[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1576
1. Timurağaoğlu A, Uğur-Bilgin A, Colak D, Tuncer M, Gölbaşi I, Hazar V, Kiliçarsłan B, Undar L, Demirbaş A: Posttransplant lymphoproliferative disorders in transplant recipients. Transplant Proc; 2006 Mar;38(2):641-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among 1040 transplantations, including 931 renal, 14 heart, 55 liver and 40 allogeneic peripheral blood stem cell (PBSC), 8 patients (7 male, 1 female) were diagnosed with PTLD.
  • According to the World Health Organization classification system, six patients were diagnosed as diffuse large B-cell lymphoma, one patient Burkitt's lymphoma, and one polymorphic PTLD.
  • This patient was an 8-year-old boy diagnosed with Burkitt's lymphoma at 31 months after liver transplantation.
  • [MeSH-minor] Adult. Child. Female. Heart Transplantation / immunology. Humans. Immunosuppressive Agents / therapeutic use. Incidence. Kidney Transplantation / immunology. Liver Transplantation / immunology. Male. Middle Aged. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549195.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


2. Tueger S, Chen FE, Ahsan G, McDonald V, Andrews VE, Madrigal JA, Kazmi MA: Thalidomide induced remission of refractory diffuse large B-Cell Lymphoma post-allogeneic SCT. Haematologica; 2006 Jun;91(6 Suppl):ECR16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide induced remission of refractory diffuse large B-Cell Lymphoma post-allogeneic SCT.
  • Patients who relapse after High dose therapy and autologous stem cell transplant (ASCT) for Diffuse large B cell Lymphoma (DLBCL) have a poor prognosis with a median survival of only 3-6 month.1-2 This case demonstrates the ability of thalidomide at low doses to induce durable response in a patient with DLBCL who relapsed after full intensity allogeneic transplantation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Stem Cell Transplantation. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Remission Induction. Transplantation, Homologous

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785122.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


3. Paul T, Challa S, Tandon A, Panigrahi M, Purohit A: Primary central nervous system lymphomas: Indian experience, and review of literature. Indian J Cancer; 2008 Jul-Sep;45(3):112-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary central nervous system lymphomas (PCNSLs) are a rare form of non-Hodgkin's lymphoma which arise within and remain confined primarily to the central nervous system (CNS).
  • Presence of lymphadenopathy, organomegaly and bone marrow study was done to exclude the possibility of secondary involvement by lymphoma.
  • All cases were diffuse large cell lymphomas on histopathology.
  • There was a single case of CD 3 positive T-cell lymphoma.
  • In the present study, PCNSLs occurred in young immunocompetent patients and majority were diffuse large B cell lymphomas.
  • [MeSH-major] Brain Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / metabolism. Antigens, CD3 / metabolism. Antigens, CD45 / metabolism. Child. Female. Humans. Immunocompetence. Immunoenzyme Techniques. India / epidemiology. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018115.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


Advertisement
4. Dhillon WS, Shah T: Images in clinical medicine. Diplopia in a patient with HIV infection. N Engl J Med; 2010 Apr 15;362(15):e52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Diplopia / etiology. HIV Infections / complications. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adult. Brain / pathology. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20393172.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Niitsu N, Kohri M, Hagiwara Y, Tanae K, Takahashi N, Bessho M, Okamoto M: Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma. Hematol Oncol; 2010 Jun;28(2):68-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma.
  • The R-CHOP regimen has been found to improve the outcome of diffuse large B-cell lymphoma (DLBCL).
  • The 5-year PFS of the germinal centre B-cell group was 80% and that of the non-GCB group was 74% (NS).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Murine-Derived. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neutropenia / chemically induced. Prednisolone / administration & dosage. Prednisolone / adverse effects. Prognosis. Rituximab. Thrombocytopenia / chemically induced. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 John Wiley & Sons, Ltd.
  • (PMID = 20235332.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 11056-06-7 / Bleomycin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; PACEBO protocol
  •  go-up   go-down


6. Lee JJ, Kim DH, Lee NY, Sohn SK, Kim JG, Kim HJ, Do YR, Park YH: Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas. Br J Haematol; 2007 May;137(4):329-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas.
  • Interleukin-10 (IL-10) is one of the cytokines implicated in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) in which it acts as auto/paracrine growth factor for lymphoma growth.
  • T-cell non-Hodgkin lymphoma (NHL) is a heterogeneous disease, the biological basis of which is not fully understood.
  • Some evidence suggests that IL-10 might be associated with the progression of T-cell NHLs and that IL-10 may be involved in a rescue effect, protecting T cells from apoptotic cell death associated with upregulated bcl-2 expression.
  • The current study evaluated the impact of IL-10 gene (IL10) polymorphism on the response to chemotherapy and survival in T-cell NHL.
  • IL10 polymorphisms were determined in 108 patients with T-cell NHL.
  • In conclusion, IL10 polymorphism may affect the survival of T-cell NHL patients.
  • [MeSH-major] Interleukin-10 / genetics. Lymphoma, Non-Hodgkin / genetics. Lymphoma, T-Cell / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Haplotypes. Humans. Male. Middle Aged. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17408400.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 130068-27-8 / Interleukin-10
  •  go-up   go-down


7. Mildon KH, Ansell P, Roman E, Kane EV: Reproductive factors, menopausal hormone therapy, and risk of non-Hodgkin, diffuse large B-cell and follicular lymphomas: a UK case-control study. Cancer Causes Control; 2010 Dec;21(12):2079-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproductive factors, menopausal hormone therapy, and risk of non-Hodgkin, diffuse large B-cell and follicular lymphomas: a UK case-control study.
  • BACKGROUND: Most non-Hodgkin lymphoma (NHL) subtypes occur more among men than women.
  • Among postmenopausal women, hormone therapy (HT) users had risks of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) below one compared to non-users (OR = 0.7, 95% CI 0.5,1.2; OR = 0.6, 95% CI 0.4,1.0, respectively).
  • CONCLUSION: For greater power to investigate the association of hormones with DLBCL, FL, and rarer NHL subtypes, pooling data through the International Lymphoma Epidemiology Consortium (InterLymph) is warranted.
  • [MeSH-major] Estrogen Replacement Therapy / statistics & numerical data. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / etiology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Reproduction / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Great Britain / epidemiology. Humans. Menopause / drug effects. Menopause / physiology. Middle Aged. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20697798.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


8. Akbayir O, Güngördük K, Gülkilik A, Yavuz E, Tekirdağ AI, Odabaş E: Successful treatment of primary vaginal diffuse large B-cell lymphoma using chemotherapy. Taiwan J Obstet Gynecol; 2008 Sep;47(3):334-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of primary vaginal diffuse large B-cell lymphoma using chemotherapy.
  • CASE REPORT: A 34-year-old female virgin patient with a primary vaginal NHL stage IEA, diffuse large cell B lineage, showed an excellent response to cytotoxic chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) without surgery or radiotherapy.
  • CONCLUSION: In young patients who wish to preserve their fertility, chemotherapy alone may be the treatment of choice for primary diffuse large B-cell NHL of the lower female genital tract.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Vaginal Neoplasms / drug therapy. Vaginal Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Immunohistochemistry. Prednisone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936000.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  • [Number-of-references] 19
  •  go-up   go-down


9. Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y, Morishima Y, Takeuchi K, Izumo T, Mori S, Ohshima K, Suzumiya J, Nakamura N, Abe M, Ichimura K, Sato Y, Yoshino T, Naoe T, Shimoyama Y, Kamiya Y, Kinoshita T, Nakamura S: Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res; 2007 Sep 1;13(17):5124-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients.
  • PURPOSE: We have recently reported EBV+ B-cell lymphoproliferative disorders (LPD) occurring predominantly in elderly patients, which shared features of EBV+ B-cell neoplasms arising in the immunologically deteriorated patients despite no predisposing immunodeficiency and were named as senile or age-related EBV+ B-cell LPDs.
  • To further characterize this disease, age-related EBV+ B-cell LPDs were compared with EBV-negative diffuse large B-cell lymphomas (DLBCL).
  • EXPERIMENTAL DESIGN: Among 1,792 large B-cell LPD cases, 96 EBV+ cases with available clinical data set were enrolled for the present study.
  • RESULTS: Patients with age-related EBV+ B-cell LPDs showed a higher age distribution and aggressive clinical features or parameters than EBV-negative DLBCLs: 44% with performance status >1, 58% with serum lactate dehydrogenase level higher than normal, 49% with B symptoms, and higher involvement of skin and lung.
  • CONCLUSIONS: These findings suggest that age-related EBV+ B-cell LPDs constitute a distinct group, and innovative therapeutic strategies such as EBV-targeted T-cell therapy should be developed for this uncommon disease.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. CD4-Positive T-Lymphocytes / immunology. Female. Hodgkin Disease / pathology. Humans. Immunophenotyping. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785567.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Ameen R, Sajnani KP, Albassami A, Refaat S: Frequencies of non-Hodgkin's lymphoma subtypes in Kuwait: comparisons between different ethnic groups. Ann Hematol; 2010 Feb;89(2):179-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequencies of non-Hodgkin's lymphoma subtypes in Kuwait: comparisons between different ethnic groups.
  • There is a wide variation in the prevalence of various subtypes of non-Hodgkin's lymphoma worldwide.
  • The aim of this study was to determine the relative frequency of different subtypes of non-Hodgkin's lymphoma in Kuwait based on the Revised European-American Lymphoma (REAL) classification.
  • From 1998 to 2006, 738 subjects were included that were registered with non-Hodgkin's lymphoma in the population-based cancer registry at the Kuwait Cancer Control Center.
  • The prevalence of different types of non-Hodgkin's lymphoma was determined based on age, sex, site of disease, and ethnicity.
  • The prevalence of B- and T-cell lymphomas was 81.8% and 14.2%, respectively.
  • The three most common subtypes in Kuwaiti Arabs were diffuse large B-cell lymphoma (46.5%), follicular lymphoma (15.5%), and mycosis fungoides (9.3%).
  • In non-Kuwaiti Arabs, the most common subtypes were diffuse large B-cell lymphoma (48%), B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia (15.8%), and follicular lymphoma (12.7%).
  • Compared to the Western world, Kuwait had a lower prevalence of follicular lymphoma, a higher prevalence of diffuse large B-cell lymphoma and extranodal presentation, and a high frequency of mycosis fungoides.
  • Compared to other parts of Asia, Kuwait had a lower frequency of peripheral T-cell lymphomas.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / ethnology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Female. Humans. Kuwait / epidemiology. Male. Middle Aged. Prevalence. Sex Distribution. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711076.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Wada N, Ikeda J, Kohara M, Ogawa H, Hino M, Fukuhara S, Kanamaru A, Sugiyama H, Kanakura Y, Morii E, Aozasa K: Diffuse large B-cell lymphoma with a high number of epithelioid histiocytes (lymphoepithelioid B-cell lymphoma): a study of Osaka Lymphoma Study Group. Virchows Arch; 2009 Sep;455(3):285-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma with a high number of epithelioid histiocytes (lymphoepithelioid B-cell lymphoma): a study of Osaka Lymphoma Study Group.
  • The aim of this study was to clarify whether diffuse large B-cell lymphoma (DLBCL) with a high number of epithelioid histiocytes (DLBCL-EH) could have distinctive clinicopathological characteristics.
  • Histologically, there was a diffuse proliferation of large lymphoid cells admixed with numerous clusters of epithelioid histiocytes sprinkling throughout the lesions.
  • Immunohistochemically, the large lymphoid cells were CD20(+), CD15(-), and CD3(-) and positive for CD10, bcl-6, and MUM1 in nine (41%), eight (36%), and 12 (55%) of 22 cases, respectively.
  • [MeSH-major] Histiocytes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1764-73 [17786712.001]
  • [Cites] Leuk Res. 2004 Mar;28(3):229-36 [14687617.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2765-3775 [19096012.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Histopathology. 2002 Jan;40(1):31-45 [11903596.001]
  • [Cites] Pediatr Blood Cancer. 2008 Oct;51(4):557-9 [18523988.001]
  • [Cites] Am J Surg Pathol. 1992 Apr;16(4):351-63 [1373580.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] J Clin Exp Hematop. 2007 Apr;47(1):23-6 [17510535.001]
  • [Cites] Eur J Haematol. 2007 Dec;79(6):501-7 [17986209.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1271-7 [12663714.001]
  • [Cites] Cancer. 1978 Feb;41(2):562-7 [630538.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Am J Clin Pathol. 1995 Jan;103(1):65-75 [7817948.001]
  • [Cites] Oncologist. 2006 Apr;11(4):384-92 [16614234.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • (PMID = 19727807.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


12. Muris JJ, Cillessen SA, Vos W, van Houdt IS, Kummer JA, van Krieken JH, Jiwa NM, Jansen PM, Kluin-Nelemans HC, Ossenkoppele GJ, Gundy C, Meijer CJ, Oudejans JJ: Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood; 2005 Apr 1;105(7):2916-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas.
  • We used biopsy specimens of primary nodal diffuse large B-cell lymphoma (DLBCL) to investigate whether the inhibition of caspase 8 and/or 9 apoptosis signaling pathways predicts clinical outcome.
  • Expression levels of cellular FLICE inhibitory protein (c-Flip) and numbers of active caspase 3-positive lymphoma cells were used to determine the status of the caspase 8-mediated pathway.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Caspases / metabolism. Etoposide / administration & dosage. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Signal Transduction / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Apoptosis / drug effects. Apoptosis / physiology. CASP8 and FADD-Like Apoptosis Regulating Protein. Caspase 3. Caspase 8. Caspase 9. Female. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins / metabolism. Male. Middle Aged. Poly(ADP-ribose) Polymerases / metabolism. Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Treatment Outcome. X-Linked Inhibitor of Apoptosis Protein

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15576477.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / CFLAR protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human; 6PLQ3CP4P3 / Etoposide; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / CASP9 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9; EC 3.4.22.- / Caspases
  •  go-up   go-down


13. Yun J, Kim SJ, Won JH, Choi CW, Eom HS, Kim JS, Kim MK, Kwak JY, Kim WS, Suh C: Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report. Leuk Res; 2010 Sep;34(9):1175-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report.
  • Fourteen patients had primary ovarian lymphoma, while eighteen patients had secondary ovarian involvement.
  • There was no significant difference in survival rates between primary and secondary involvement with diffuse large B-cell lymphoma (DLBCL), the most common subtype.
  • Treatment outcomes of secondary ovarian involvement in non-Hodgkin's lymphoma were comparable to those of primary ovarian involvement, suggesting that ovarian involvement does not necessarily predict a worse prognosis for NHL patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20206997.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


14. Li XX, Chen YZ, Li F, Hu WH, Li HA, Jiang JF: [Application of detection of clonal immunoglobulin heavy chain gene rearrangement in paraffin-embedded tissues from B-cell non-Hodgkin lymphomas]. Zhonghua Bing Li Xue Za Zhi; 2007 Feb;36(2):126-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of detection of clonal immunoglobulin heavy chain gene rearrangement in paraffin-embedded tissues from B-cell non-Hodgkin lymphomas].
  • [MeSH-major] DNA, Neoplasm / genetics. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Immunoglobulin Heavy Chains / genetics. Lymphoma, B-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / genetics. Male. Middle Aged. Paraffin Embedding. Polymerase Chain Reaction. Young Adult

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493389.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


15. Torlakovic EE, Bilalovic N, Golouh R, Zidar A, Angel S: Prognostic significance of PU.1 in follicular lymphoma. J Pathol; 2006 Jul;209(3):352-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of PU.1 in follicular lymphoma.
  • Very few prognostic factors are known in follicular lymphoma (FL), a common malignancy of germinal centre (GC) B-cells.
  • The Follicular Lymphoma International Prognostic Index (FLIPI) thus far appears to be the most important predictor of clinical outcome.
  • Results for PFS were independent of the International Prognostic Index or the Italian Lymphoma Intergroup prognostic index for CD75 and PU.1, but only PU.1 expression was independent of FLIPI for PFS and OS.
  • Oct-2 was weakly expressed overall, but more strongly in higher grades of FL; it had a trend for negative linear association with PU.1 and strong positive linear association with CD27, which possibly reflects its role in terminal B-cell differentiation.
  • While this is determined qualitatively in most studies of diffuse large B-cell lymphoma, in FL there is a quantitative positive association between a high level of expression of GC antigens and longer OS and PFS even when data are stratified by the FLIPI score.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Lymphoma, Follicular / diagnosis. Proto-Oncogene Proteins / metabolism. Trans-Activators / metabolism
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Antigens, CD20 / metabolism. Antigens, CD27 / metabolism. Female. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm Proteins / metabolism. Octamer Transcription Factor-2 / metabolism. Prognosis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Sialyltransferases. Survival Analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Follicular lymphoma 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 16639693.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD20; 0 / Antigens, CD27; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-2; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Trans-Activators; 0 / proto-oncogene protein Spi-1; EC 2.4.99.- / Sialyltransferases; EC 2.4.99.1 / ST6GAL1 protein, human
  •  go-up   go-down


16. Wood L, Robinson R, Gavine L, Juritz J, Jacobs P: A single unit lymphoma experience: outcome in a Cape Town academic centre. Transfus Apher Sci; 2007 Aug;37(1):93-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single unit lymphoma experience: outcome in a Cape Town academic centre.
  • Fifty-seven percent were stage I or II and 21% had nodal disease above and below the diaphragm whilst in the remainder cells were present in the circulation and this included the subset of chronic lymphocytic leukaemia -- small lymphocytic lymphoma.
  • Analysed by disease category Hodgkin lymphoma (n=17) when managed according to the German Study Group protocols and hairy cell leukaemia (n=10) treated with two chlorodeoxyadenosine -- both had a stable plateau in excess of 90%.
  • Curves for the aggressive or diffuse large B-cell lymphoma (n=44) fell initially to 48%, but relapse continued in stages III and IV to the current level of 18% when receiving cyclophosphamide, hydroxydaunorubicin, vincristine and prednisone on the 21-day schedule.
  • Chronic lymphocytic leukaemia -- small lymphocytic lymphoma (n=58) were initially given pulsed chlorambucil and sustained response was over 90% with low bulk, but declined to reach 30% as prognostic score rose.
  • [MeSH-major] Hospitals, Private. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma / mortality. Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Child. Cohort Studies. Developing Countries. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Risk Factors. South Africa. Survival Rate

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931976.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


17. Seki R, Ohshima K, Fujisaki T, Uike N, Kawano F, Gondo H, Makino S, Eto T, Moriuchi Y, Taguchi F, Kamimura T, Tsuda H, Ogawa R, Shimoda K, Yamashita K, Suzuki K, Suzushima H, Tsukazaki K, Higuchi M, Utsunomiya A, Iwahashi M, Imamura Y, Tamura K, Suzumiya J, Yoshida M, Abe Y, Matsumoto T, Okamura T: Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci; 2009 Oct;100(10):1842-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
  • We evaluated the usefulness of prognostic markers in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide, vincristine, doxorubicin, and prednisolone (CHOP) +/- rituximab (R-CHOP) in Japan.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / analysis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / genetics. Doxorubicin / administration & dosage. Drug Resistance, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Interferon Regulatory Factors / biosynthesis. Interferon Regulatory Factors / genetics. Kaplan-Meier Estimate. Male. Middle Aged. Neprilysin / biosynthesis. Neprilysin / genetics. Prednisone / administration & dosage. Prognosis. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Proto-Oncogene Proteins c-bcl-2 / genetics. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19656156.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / interferon regulatory factor-4; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.24.11 / Neprilysin; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


18. Zekri AR, Mohamed W, Bahnassy A, Refat L, Khaled M, Shalaby S, Hafez M: Detection of simian virus 40 DNA sequences in Egyptian patients with different hematological malignancies. Leuk Lymphoma; 2007 Sep;48(9):1828-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SV40 DNA sequences have been detected in non-Hodgkin's lymphoma patients.
  • The highest frequency was in Burkitt's lymphoma followed by diffuse large B-cell lymphoma.
  • The present study suggests that SV40 is significantly associated with non-Hodgkin's lymphoma and most probably acts as a cofactor in the pathogenesis of these tumors.
  • [MeSH-major] DNA, Viral / analysis. Lymphoma, Non-Hodgkin / virology. Simian virus 40 / isolation & purification
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Sequence Analysis, DNA

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786720.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


19. Park BB, Kim JS, Lee YY, Kang HJ, Ryoo BY, Kang JH, Kim HY, Kim BS, Oh SY, Kwon HC, Won JH, Kim K, Park K, Suh C, Kim WS: Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. Leuk Lymphoma; 2008 Jan;49(1):88-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma.
  • Several previous studies have addressed the association between hepatitis C virus (HCV) infection and non-Hodgkin lymphoma (NHL), but there are few studies on HCV-related diffuse large B-cell lymphoma (DLBL).
  • [MeSH-major] Hepacivirus. Lymphoma, Large B-Cell, Diffuse / virology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Humans. Korea. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18203017.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


20. Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD, Connors JM: Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol; 2006 Jan;17(1):123-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
  • BACKGROUND: Primary mediastinal large B-cell lymphoma (PMBCL) is a distinct clinico-pathological subtype of diffuse large B-cell lymphoma (DLBCL).
  • PATIENTS AND METHODS: The British Columbia Cancer Agency lymphoma database was searched and records reviewed to identify those patients presenting with a prominent mediastinal mass and considered to be PMBCL based on the current REAL/WHO classifications.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236753.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


21. Attygalle AD, Kyriakou C, Dupuis J, Grogg KL, Diss TC, Wotherspoon AC, Chuang SS, Cabeçadas J, Isaacson PG, Du MQ, Gaulard P, Dogan A: Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol; 2007 Jul;31(7):1077-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression.
  • Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon, but aggressive nodal peripheral T-cell lymphoma.
  • Eleven cases where polymerase chain reaction results for T-cell receptor-gamma gene rearrangement were directly compared showed an identical band-size in the initial and follow-up biopsies.
  • Seven cases (23%) developed EBV-associated B-cell lymphomas [5 diffuse large B-cell lymphoma (DLBCL) and 2 classic Hodgkin lymphoma].
  • In 4 cases, a dominant B-cell clone was observed in biopsies lacking evidence of DLBCL.
  • A single case was complicated by EBV-negative DLBCL, whereas another with large cell transformation had a T-cell phenotype.
  • In conclusion, AITL represents a clonal T-cell proliferation with a stable T-cell clone throughout the disease.
  • When "morphologic high-grade transformation" occurs, it is usually due to a secondary (often EBV-associated) B-cell lymphoma, rather than a T-cell neoplasm.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, T-Cell, Peripheral / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Biopsy. Clone Cells / metabolism. Clone Cells / pathology. Disease Progression. Disease-Free Survival. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / metabolism. Epstein-Barr Virus Infections / pathology. Female. Gene Rearrangement, T-Lymphocyte. Herpesvirus 4, Human / isolation & purification. Humans. In Situ Hybridization. Male. Middle Aged. Neoplasm Staging. RNA, Viral / analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592275.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Viral
  •  go-up   go-down


22. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2005 Feb 1;23(4):667-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
  • PURPOSE: Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or arm B (other B-cell lymphomas) without limitation in number of prior therapies.
  • RESULTS: Sixty patients with a median number of prior therapies of 3.5 (range, one to 12 therapies) were enrolled; 33 patients were in arm A and 27 were in arm B, including 12 diffuse large B-cell lymphomas, five follicular lymphomas (FL), three transformed FLs, four small lymphocytic lymphomas (SLL), two Waldenstrom's macroglobulinemias (WM), and one marginal zone lymphoma.
  • In arm B, four of 21 assessable patients responded (one SLL patient had a CR, one FL patient had a CR unconfirmed, one diffuse large B-cell lymphoma patient had a PR, and one WM patient had a PR) for an ORR of 19% (95% CI, 5% to 42%).
  • CONCLUSION: Bortezomib showed promising activity in relapsed mantle-cell lymphoma and encouraging results in other B-cell lymphomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Lymphoma, B-Cell / drug therapy. Protease Inhibitors / therapeutic use. Pyrazines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bortezomib. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Feb 1;23(4):657-8 [15613690.001]
  • (PMID = 15613697.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


23. Mitrovic Z, Ilic I, Nola M, Aurer I, Sonicki Z, Basic-Kinda S, Radman I, Ajdukovic R, Labar B: CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma. Clin Lymphoma Myeloma; 2009 Apr;9(2):133-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma.
  • About a quarter of diffuse large B-cell lymphomas (DLBCLs) express CD43, but its prognostic significance is unknown.
  • [MeSH-major] Antigens, CD43 / biosynthesis. Biomarkers, Tumor / biosynthesis. Lymphoma, Large B-Cell, Diffuse / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Prednisone / administration & dosage. Retrospective Studies. Rituximab. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19406723.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD43; 0 / Biomarkers, Tumor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


24. Sakurai N, Tateoka K, Taguchi J, Terada T: Primary precursor B-cell lymphoblastic lymphoma of the ovary: case report and review of the literature. Int J Gynecol Pathol; 2008 Jul;27(3):412-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary precursor B-cell lymphoblastic lymphoma of the ovary: case report and review of the literature.
  • Primary ovarian lymphoma is a rare disease, and its definition is still controversial.
  • Many cases of primary ovarian lymphoma are diagnosed as diffuse large B-cell type, whereas the precursor lymphoblastic type is extremely rare.
  • Herein, we describe a case of precursor B-cell lymphoblastic lymphoma of the ovary that was successfully treated with surgery and chemotherapy.
  • Exploratory laparotomy and right salpingo-oophorectomy were performed, and the diagnosis of precursor B-cell lymphoblastic lymphoma was established.
  • To our best knowledge, this is the fourth reported case of precursor lymphoblastic lymphoma of the ovary.
  • [MeSH-major] Ovarian Neoplasms / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580320.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


25. Yun J, Kim SJ, Kim JA, Kong JH, Lee SH, Kim K, Ko YH, Kim WS: Clinical features and treatment outcomes of non-Hodgkin's lymphomas involving rare extranodal sites: a single-center experience. Acta Haematol; 2010;123(1):48-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The involvement of certain organs such as the adrenal gland and ovaries is rare in non-Hodgkin's lymphoma (NHL).
  • Diffuse large B-cell lymphoma (DLBCL) was the most common (n = 39), and the median overall survival (OS) was 16.63 months.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / therapy. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Kaplan-Meier Estimate. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / therapy. Prednisone / therapeutic use. Prognosis. Rituximab. Treatment Outcome. Vincristine / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 S. Karger AG, Basel.
  • (PMID = 19955711.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


26. Sun XF, Liu DG, Zhen ZJ, Chen XQ, Xia Y, Wang ZH, He YJ, Guan ZG: [Efficacy of short-term and intensive chemotherapy for the treatment of childhood and adolescent B cell non-Hodgkin's lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2005 Oct;26(10):581-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of short-term and intensive chemotherapy for the treatment of childhood and adolescent B cell non-Hodgkin's lymphoma].
  • OBJECTIVES: To evaluate the efficacy and toxicity of the B-NHL-BFM-90 protocol in the treatment of Chinese childhood and adolescent B-cell non-Hodgkin's lymphomas (B-NHL).
  • Of them 18 cases were Burkitt's lymphoma, 16 diffuse large B cell lymphoma and 8 anaplastic lymphoma.
  • Of the 5 PR patients, I received autologous hematopoietic stem cell transplantation, 3 received radiotherapy for residual disease and 1 just under watching.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Feasibility Studies. Female. Follow-Up Studies. Humans. Infant. Male. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16532964.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


27. De Paepe P, Achten R, Verhoef G, Wlodarska I, Stul M, Vanhentenrijk V, Praet M, De Wolf-Peeters C: Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol; 2005 Oct 1;23(28):7060-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas.
  • PURPOSE: The reliability of immunohistochemistry for subdividing diffuse large B-cell lymphomas (DLBCL) into germinal center B-cell-like (GCB) and non-GCB prognostic subgroups is debated.
  • PATIENTS AND METHODS: All samples from patients were reviewed and morphologically subdivided into large cleaved, immunoblastic, and not otherwise specified DLBCL.
  • Interestingly, large cleaved DLBCL was clearly associated with a GCB immunophenotypic profile, CD10 expression, BCL2 rearrangement, age younger than 60 years, and low to low/intermediate International Prognostic Index risk, but was not of prognostic significance.
  • Nevertheless, it allowed the additional characterization of two lymphoma subgroups previously recognized in the Working Formulation.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. DNA-Binding Proteins / genetics. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neprilysin / biosynthesis. Prognosis. Reproducibility of Results. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129841.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


28. Hartge P, Lim U, Freedman DM, Colt JS, Cerhan JR, Cozen W, Severson RK, Davis S: Ultraviolet radiation, dietary vitamin D, and risk of non-Hodgkin lymphoma (United States). Cancer Causes Control; 2006 Oct;17(8):1045-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultraviolet radiation, dietary vitamin D, and risk of non-Hodgkin lymphoma (United States).
  • OBJECTIVE: Because of conflicting findings about the relationship between ultraviolet (UV) radiation and the risk of non-Hodgkin lymphoma (NHL), we evaluated the risk of several indicators related to UV, including two not previously studied: dietary vitamin D, and ambient UV levels by residential location.
  • Effects were generally similar for diffuse large B-cell (DLBCL) and follicular lymphomas.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Ultraviolet Rays. Vitamin D / administration & dosage. Vitamin D / pharmacology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Confidence Intervals. Female. Humans. Interviews as Topic. Male. Middle Aged. Risk Factors. Surveys and Questionnaires. United States

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933055.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / CP / N02-CP-31003; United States / NCI NIH HHS / PC / N02-PC-71105; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  •  go-up   go-down


29. Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G: Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol; 2008 Apr;87(4):277-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.
  • The treatment of diffuse large B-cell lymphoma with chemotherapy was retrospectively evaluated in 348 patients who had received at least three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like, ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone)-like or CHVmP-BV (cyclophosphamide, hydroxorubicin, Vm-26, prednisone, vincristine and bleomycin) treatment in Belgium between 1995 and 2000.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Bleomycin / pharmacokinetics. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / pharmacokinetics. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / pharmacokinetics. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Lymphoma / classification. Lymphoma / drug therapy. Lymphoma / mortality. Lymphoma / radiotherapy. Patient Selection. Prednisone / administration & dosage. Prednisone / pharmacokinetics. Retrospective Studies. Survival Analysis. Time Factors. Vindesine / administration & dosage. Vindesine / pharmacokinetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952688.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; LNH 87 protocol
  •  go-up   go-down


30. Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, Munden RF: Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med; 2006 Aug;47(8):1267-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our objective was to evaluate the accuracy of PET/CT for the diagnosis of Richter's transformation of chronic lymphocytic leukemia (CLL) to diffuse large cell lymphoma.
  • Nine patients had false-positive PET/CT findings; in 3 of these patients, alternative malignancies were diagnosed (Hodgkin's disease; metastatic neuroendocrine carcinoma; non-small cell lung cancer).
  • For the specific diagnosis of Richter's transformation of CLL to diffuse large B-cell lymphoma, PET/CT had overall sensitivity, specificity, and positive and negative predictive values of 91%, 80%, and 53% and 97%, respectively.
  • CONCLUSION: PET/CT can detect Richter's transformation of CLL to diffuse large B-cell lymphoma with a high sensitivity and a high negative predictive value.
  • [MeSH-major] Cell Transformation, Neoplastic. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / radionuclide imaging. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Observer Variation. Predictive Value of Tests. Retrospective Studies

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883004.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L, Zain J, Patane K, Kogut N, Nakamura R, Sarkodee-Adoo C, Forman SJ: Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant; 2006 Dec;12(12):1326-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
  • Reduced-intensity regimens (RIRs) are being used with increasing frequency in patients with non-Hodgkin's lymphoma (NHL) undergoing allogeneic transplantation.
  • [MeSH-major] Lymphoma, Non-Hodgkin / surgery. Peripheral Blood Stem Cell Transplantation / statistics & numerical data. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Busulfan / administration & dosage. Busulfan / adverse effects. Cause of Death. Cohort Studies. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Hepatic Veno-Occlusive Disease / etiology. Hepatic Veno-Occlusive Disease / mortality. Humans. Infection / etiology. Infection / mortality. Kaplan-Meier Estimate. Lung Diseases, Interstitial / etiology. Lung Diseases, Interstitial / mortality. Lymphoma, Follicular / mortality. Lymphoma, Follicular / surgery. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / surgery. Lymphoma, Mantle-Cell / mortality. Lymphoma, Mantle-Cell / surgery. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / surgery. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Postoperative Complications / etiology. Postoperative Complications / mortality. Proportional Hazards Models. Reoperation / statistics & numerical data. Retrospective Studies. Risk Factors. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / adverse effects. Vidarabine / analogs & derivatives. Whole-Body Irradiation / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162215.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


32. Wang J, Chen C, Lau S, Raghavan RI, Rowsell EH, Said J, Weiss LM, Huang Q: CD3-positive large B-cell lymphoma. Am J Surg Pathol; 2009 Apr;33(4):505-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD3-positive large B-cell lymphoma.
  • It is not uncommon for some B-lineage non-Hodgkin lymphomas (NHLs) to aberrantly coexpress T-cell markers, particularly CD5, as well as CD7, CD2, CD4, and/or CD8 in rare cases.
  • Cases of CD3-positive B-cell NHL, however, have not previously been described in the literature.
  • We present 4 cases of large B-cell lymphoma aberrantly coexpressing T-cell marker CD3 and B-lineage markers as well as demonstrating clonal rearrangement of the immunoglobulin genes but not the gamma T-cell receptor gene.
  • To our knowledge, this represents the first series report of B-cell NHL coexpressing T-lineage-specific marker CD3.
  • The identification of such cases indicates that the use of CD3 antibody alone in paraffin sections may lead to an incorrect determination of cell lineage in some B-cell NHL.
  • Immunohistochemistry using additional cell lineage specific markers or molecular analysis for antigen receptor gene rearrangements are necessary for correct determination of the cell lineage in such cases.
  • [MeSH-major] Antigens, CD3 / analysis. B-Lymphocytes / pathology. Biomarkers, Tumor / analysis. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Aged, 80 and over. Clone Cells. DNA, Neoplasm / analysis. Female. Gene Rearrangement. Genes, Immunoglobulin / genetics. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Viral / analysis. RNA-Binding Proteins / analysis. Ribosomal Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011566.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Viral; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


33. Pienkowska-Grela B, Witkowska A, Grygalewicz B, Rymkiewicz G, Rygier J, Woroniecka R, Walewski J: Frequent aberrations of chromosome 8 in aggressive B-cell non-Hodgkin lymphoma. Cancer Genet Cytogenet; 2005 Jan 15;156(2):114-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent aberrations of chromosome 8 in aggressive B-cell non-Hodgkin lymphoma.
  • Translocations involving chromosome 8 are the most common aberrations in B-cell non-Hodgkin lymphoma (B-NHL).
  • The presence of the typical t(8;14)(q24;q32) or its variants has been confirmed in all cases of Burkitt lymphoma (BL), in some cases of Burkitt-like lymphoma (BLL), and in diffuse large B-cell lymphoma (DLBCL).
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 8. Lymphoma, B-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosome Banding. Chromosome Mapping. Chromosomes, Human, Pair 14. Female. Flow Cytometry. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Translocation, Genetic. Tumor Cells, Cultured


34. Kumari N, Krishnani N, Rawat A, Agarwal V, Lal P: Primary central nervous system lymphoma: prognostication as per international extranodal lymphoma study group score and reactive CD3 collar. J Postgrad Med; 2009 Oct-Dec;55(4):247-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma: prognostication as per international extranodal lymphoma study group score and reactive CD3 collar.
  • BACKGROUND: Primary central nervous system (CNS) lymphoma is being increasingly recognized in immunosuppressed as well as immunocompetent individuals.
  • It has a poor prognosis and the majority of these have diffuse large B-cell type of morphology.
  • AIM: To categorize cases of primary CNS lymphoma according to the International Extranodal Lymphoma Study Group (IELSG) score and to correlate the score with reactive CD3 collar around blood vessels and necrosis.
  • MATERIALS AND METHODS: We reviewed the clinico-pathological, morphological and immuno-histochemical features of 30 cases of primary CNS lymphoma reported at our institute in the last nine years and categorized them according to the score given by IELSG.
  • RESULTS: All our cases were HIV-negative and had diffuse large cell histology.
  • This histological marker could be supplemented with IELSG score to stratify the patients of primary CNS lymphoma according to their aggressiveness.
  • [MeSH-major] B-Lymphocytes / pathology. Central Nervous System Neoplasms / pathology. Lymphoma / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD3 / immunology. Biomarkers, Tumor / metabolism. Female. Humans. India. Male. Middle Aged. Necrosis. Prognosis. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Postgrad Med. 2009 Oct-Dec;55(4):240-1 [20083867.001]
  • (PMID = 20083869.001).
  • [ISSN] 0972-2823
  • [Journal-full-title] Journal of postgraduate medicine
  • [ISO-abbreviation] J Postgrad Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Biomarkers, Tumor
  •  go-up   go-down


35. Ueda Y, Marusawa H, Ichinohe T, Kadowaki N, Uchiyama T, Chiba T: Effective treatment for de novo hepatitis B with nucleotide analogue in patients with hematological malignancies. Am J Hematol; 2009 May;84(5):315-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antiviral Agents / therapeutic use. Guanine / analogs & derivatives. Hepatitis B. Lamivudine / therapeutic use. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cervix Uteri / pathology. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Prednisone / therapeutic use. Recurrence. Remission Induction. Stomach / pathology. Transplantation, Autologous. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19350661.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 2T8Q726O95 / Lamivudine; 5968Y6H45M / entecavir; 5J49Q6B70F / Vincristine; 5Z93L87A1R / Guanine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; EPOCH protocol
  •  go-up   go-down


36. Han X, Zheng T, Foss FM, Ma S, Holford TR, Boyle P, Leaderer B, Zhao P, Dai M, Zhang Y: Alcohol consumption and non-Hodgkin lymphoma survival. J Cancer Surviv; 2010 Jun;4(2):101-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alcohol consumption and non-Hodgkin lymphoma survival.
  • Alcohol drinking has also been associated with reduced risk of non-Hodgkin lymphoma (NHL).
  • Analysis by NHL subtype shows that the favorable effect of wine consumption was mainly seen for patients diagnosed with diffuse large B-cell lymphoma (DLBCL) (wine drinkers for more than 25 years vs. never drinkers: HR = 0.36, 95% CI 0.14-0.94 for overall survival; HR = 0.38, 95% CI 0.16-0.94 for disease-free survival), and the adverse effect of liquor consumption was also observed among DLBCL patients (liquor drinkers vs. never drinkers: HR=2.49, 95% CI 1.26-4.93 for disease-free survival).

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Alcohol.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Lancet Oncol. 2009 Nov;10(11):1033-4 [19891056.001]
  • [Cites] Ital Heart J. 2001 Jan;2(1):1-8 [11214695.001]
  • [Cites] JAMA. 2001 Sep 26;286(12):1494-7 [11572743.001]
  • [Cites] Eur J Clin Nutr. 2002 Aug;56 Suppl 3:S50-3 [12142963.001]
  • [Cites] Cancer Causes Control. 2003 Sep;14(7):687-94 [14575367.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):148-54 [14718216.001]
  • [Cites] Alcohol Alcohol. 2004 May-Jun;39(3):155-65 [15082451.001]
  • [Cites] Eur J Nutr. 2004 Oct;43(5):275-84 [15309446.001]
  • [Cites] Arch Intern Med. 1995 Feb 27;155(4):381-6 [7848021.001]
  • [Cites] BMJ. 1996 Feb 24;312(7029):478-81 [8597679.001]
  • [Cites] Am J Epidemiol. 1996 May 15;143(10):1059-68 [8629613.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Am J Epidemiol. 1999 May 15;149(10):943-9 [10342803.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1476-82 [10424754.001]
  • [Cites] Chem Biol Interact. 2005 Jan 15;151(2):143-9 [15698585.001]
  • [Cites] Mol Nutr Food Res. 2005 May;49(5):405-30 [15832402.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):469-76 [15992695.001]
  • [Cites] Biochem Pharmacol. 2006 Mar 14;71(6):742-50 [16427027.001]
  • [Cites] Curr Opin Gastroenterol. 2006 May;22(3):248-53 [16550039.001]
  • [Cites] Curr Drug Targets. 2006 Apr;7(4):423-42 [16611030.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1283-9 [16728483.001]
  • [Cites] Semin Radiat Oncol. 2007 Jan;17(1):2-9 [17185192.001]
  • [Cites] J Androl. 2007 Mar-Apr;28(2):282-93 [17050787.001]
  • [Cites] Am J Epidemiol. 2007 Sep 15;166(6):697-708 [17596266.001]
  • [Cites] Circulation. 2007 Sep 11;116(11):1306-17 [17846344.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):1918-27 [17693661.001]
  • [Cites] Angiology. 2007 Dec-2008 Jan;58(6):689-97 [18216378.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):946-55 [18245498.001]
  • [Cites] Int J Cancer. 2008 Apr 1;122(7):1624-9 [18059029.001]
  • [Cites] Mol Nutr Food Res. 2008 Apr;52(4):408-18 [18381677.001]
  • [Cites] Curr Atheroscler Rep. 2008 Apr;10(2):117-20 [18417065.001]
  • [Cites] J Agric Food Chem. 2008 Jun 25;56(12):4813-8 [18522405.001]
  • [Cites] Am Fam Physician. 2008 Jun 1;77(11):1573-8 [18581838.001]
  • [Cites] Crit Rev Food Sci Nutr. 2008 Aug;48(7):649-71 [18663616.001]
  • [Cites] Nutr Rev. 2008 Aug;66(8):445-54 [18667005.001]
  • [Cites] Nutr Res. 2008 Dec;28(12):842-50 [19083497.001]
  • [Cites] Aust Dent J. 2008 Dec;53(4):302-5 [19133944.001]
  • [Cites] J Natl Cancer Inst. 2009 Mar 4;101(5):296-305 [19244173.001]
  • [Cites] Chem Biol Interact. 2009 May 15;179(2-3):131-44 [19073162.001]
  • [Cites] Bratisl Lek Listy. 2008;109(12):590-4 [19348387.001]
  • [Cites] J Epidemiol Community Health. 2009 Jul;63(7):534-40 [19406740.001]
  • [Cites] Ann Epidemiol. 2009 Oct;19(10):746-53 [19394864.001]
  • [Cites] Epidemiology. 2001 Jan;12(1):62-7 [11138821.001]
  • (PMID = 20039144.001).
  • [ISSN] 1932-2267
  • [Journal-full-title] Journal of cancer survivorship : research and practice
  • [ISO-abbreviation] J Cancer Surviv
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA62006; United States / FIC NIH HHS / TW / D43 TW007864-01; United States / NCRR NIH HHS / RR / UL1 RR024139; United States / FIC NIH HHS / TW / D43 TW007864; United States / FIC NIH HHS / TW / D43 TW008323; United States / NCI NIH HHS / CA / R01 CA062006; United States / FIC NIH HHS / TW / 1D43TW008323-01; United States / FIC NIH HHS / TW / 1D43TW007864-01; United States / FIC NIH HHS / TW / D43 TW008323-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS172384; NLM/ PMC3141078
  •  go-up   go-down


37. Uccella S, Cerutti R, Placidi C, Marchet S, Carnevali I, Bernasconi B, Proserpio I, Pinotti G, Tibiletti MG, Furlan D, Capella C: MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression. J Clin Pathol; 2009 Aug;62(8):715-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression.
  • AIMS:. (1) To validate a quantitative real time methylation specific PCR assay (MethyLight) for the detection of O6-methylguanine-DNA methyltransferase (MGMT) gene methylation status (MS) in diffuse large B-cell lymphoma (DLBCL). (2) To determine the immunohistochemical (IHC) expression of the MGMT protein and correlate it with MS.
  • Statistical analysis of overall survival (OS), lymphoma-specific survival (LSS) and progression free survival (PFS) was performed according to IHC and MS results.
  • [MeSH-major] Biomarkers, Tumor / genetics. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosomes, Human, Pair 10 / genetics. DNA, Neoplasm / genetics. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Neoplasm Staging. Polymerase Chain Reaction / methods. Survival Analysis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19638543.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


38. Ohsawa M, Ikura Y, Fukushima H, Shirai N, Sugama Y, Suekane T, Hirayama M, Hino M, Ueda M: Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology; 2005;68(4-6):422-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma.
  • BACKGROUND/AIMS: The aim of this study was to determine whether expression of P-glycoprotein (P-gp), multidrug-resistance-related protein 1 (MRP1), and lung resistance protein (LRP) was related to the response to induction chemotherapy and prognosis in untreated diffuse large B-cell lymphoma (DLBCL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Neoplasm Proteins / metabolism. P-Glycoprotein / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adult. Aged. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Predictive Value of Tests. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020972.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein
  •  go-up   go-down


39. Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J, Hjalgrim H, Vineis P, Seniori Costantini A, Bracci PM, Holly EA, Willett E, Spinelli JJ, La Vecchia C, Zheng T, Becker N, De Sanjosé S, Chiu BC, Dal Maso L, Cocco P, Maynadié M, Foretova L, Staines A, Brennan P, Davis S, Severson R, Cerhan JR, Breen EC, Birmann B, Grulich AE, Cozen W: Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood; 2008 Apr 15;111(8):4029-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium.
  • Some autoimmune disorders are increasingly recognized as risk factors for non-Hodgkin lymphoma (NHL) overall, but large-scale systematic assessments of risk of NHL subtypes are lacking.
  • Sjögren syndrome was associated with a 6.5-fold increased risk of NHL, a 1000-fold increased risk of parotid gland marginal zone lymphoma (OR = 996; 95% CI, 216-4596), and with diffuse large B-cell and follicular lymphomas.
  • Systemic lupus erythematosus was associated with a 2.7-fold increased risk of NHL and with diffuse large B-cell and marginal zone lymphomas.
  • Hemolytic anemia was associated with diffuse large B-cell NHL.
  • T-cell NHL risk was increased for patients with celiac disease and psoriasis.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 1999 Aug;42(8):1765-72 [10446879.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2006 Sep;3(9):516-25 [16951668.001]
  • [Cites] Gut. 2005 Jan;54(1):54-9 [15591504.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):133-42 [15617998.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4 Suppl 1):S57-67 [15825128.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1668-72 [10556138.001]
  • [Cites] Eur J Cancer Prev. 2000 Feb;9(1):59-64 [10777011.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):623-39 [10800981.001]
  • [Cites] J Epidemiol Community Health. 2000 Jun;54(6):431-6 [10818118.001]
  • [Cites] Lancet. 2000 Jul 15;356(9225):203-8 [10963198.001]
  • [Cites] Arch Dermatol. 2001 Jun;137(6):778-83 [11405770.001]
  • [Cites] Stat Med. 2001 Jul 30;20(14):2115-30 [11439425.001]
  • [Cites] J Invest Dermatol. 2001 Dec;117(6):1531-7 [11886519.001]
  • [Cites] Stat Med. 2002 Jun 15;21(11):1539-58 [12111919.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1428-35 [12404215.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):518-23 [12676609.001]
  • [Cites] Nature. 2003 May 15;423(6937):356-61 [12748655.001]
  • [Cites] Autoimmun Rev. 2003 Jan;2(1):13-8 [12848970.001]
  • [Cites] Am J Epidemiol. 2003 Aug 15;158(4):316-27 [12915497.001]
  • [Cites] Arthritis Rheum. 2003 Nov;48(11):3181-6 [14613281.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1797-800 [14652242.001]
  • [Cites] N Engl J Med. 2004 Jan 15;350(3):239-48 [14724303.001]
  • [Cites] IARC Sci Publ. 2004;(157):373-92 [15055307.001]
  • [Cites] Cancer Causes Control. 2004 May;15(4):419-28 [15141141.001]
  • [Cites] Neuroepidemiology. 2004 Sep-Oct;23(5):224-7 [15316248.001]
  • [Cites] Gut. 1976 Aug;17(8):612-9 [789184.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Arthritis Rheum. 1995 Apr;38(4):551-8 [7718010.001]
  • [Cites] J Clin Gastroenterol. 1995 Sep;21(2):123-9 [8583077.001]
  • [Cites] Clin Immunol Immunopathol. 1997 Sep;84(3):223-43 [9281381.001]
  • [Cites] Eur Respir J. 1998 Oct;12(4):906-12 [9817167.001]
  • [Cites] Gut. 2005 May;54(5):617-22 [15831904.001]
  • [Cites] Arthritis Rheum. 2005 May;52(5):1481-90 [15880596.001]
  • [Cites] Ann Rheum Dis. 2005 Oct;64(10):1507-9 [16162903.001]
  • [Cites] Arch Intern Med. 2005 Nov 14;165(20):2337-44 [16287762.001]
  • [Cites] Am J Epidemiol. 2005 Dec 15;162(12):1153-61 [16251389.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):51-60 [16391371.001]
  • [Cites] J Invest Dermatol. 2006 Oct;126(10):2194-201 [16741509.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(17):3028-33 [16945522.001]
  • [Cites] Lancet. 2007 Feb 17;369(9561):587-96 [17307106.001]
  • [Cites] Tumori. 2007 Jan-Feb;93(1):1-3 [17455863.001]
  • [Cites] Dis Colon Rectum. 2007 Jun;50(6):839-55 [17308939.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4929-38 [17878393.001]
  • [Cites] J Rheumatol. 1999 Aug;26(8):1676-80 [10451061.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Feb;18(2):187-94 [16394801.001]
  • [Cites] Arthritis Rheum. 2006 Mar;54(3):692-701 [16508929.001]
  • [Cites] Ann Rheum Dis. 2006 May;65(5):617-22 [16249224.001]
  • [Cites] Ann Rheum Dis. 2006 Jun;65(6):796-803 [16284097.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1559-68 [16863561.001]
  • [CommentIn] Blood. 2008 Jun 15;111(12):5760 [18544704.001]
  • (PMID = 18263783.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA62006; United States / NCI NIH HHS / CN / N01 PC067009; United States / NCI NIH HHS / CA / CA89745; United States / NCI NIH HHS / PC / N01 PC067010; United States / NCI NIH HHS / PC / PC67009; United States / NCI NIH HHS / CA / CA45614; United States / NCI NIH HHS / CA / K07 CA115687; United States / NCI NIH HHS / PC / PC67008; United States / NCI NIH HHS / PC / N01 PC067008; United States / NCI NIH HHS / CA / CA87014; United States / NCI NIH HHS / CA / CA104682; None / None / / N01 PC065064; United States / NCI NIH HHS / CA / R01 CA062006; United States / NCI NIH HHS / PC / PC71105; United States / NCI NIH HHS / CA / R01 CA104682; United States / NCI NIH HHS / PC / PC67010; United States / NCI NIH HHS / PC / PC65064; United States / NCI NIH HHS / CA / R01 CA087014; United States / NCI NIH HHS / CA / CA51086; United States / NCI NIH HHS / CA / R01 CA051086; United States / NCI NIH HHS / CA / R01 CA045614; United States / NCI NIH HHS / CA / R03 CA089745
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2288717
  •  go-up   go-down


40. Harting R, Venugopal P, Gregory SA, O'brien T, Bogdanova E: Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma; 2007 May;7(6):406-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
  • BACKGROUND: We evaluated the efficacy and safety of adding rituximab to nonanthracycline ESHAP (etoposide/methylprednisolone/cytarabine/cisplatin) chemotherapy for relapsed/refractory aggressive non-Hodgkin lymphoma (NHL).
  • Thirteen patients were enrolled (median age, 56 years); all had previously treated NHL, 12 (92%) had diffuse large B-cell lymphoma, 10 (77%) had stage III/IV disease, and 2 (15%) had chemotherapy-refractory disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia / chemically induced. Antibodies, Monoclonal, Murine-Derived. Cisplatin / adverse effects. Cisplatin / therapeutic use. Creatinine / urine. Cytarabine / adverse effects. Cytarabine / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Male. Methylprednisolone / adverse effects. Methylprednisolone / therapeutic use. Middle Aged. Nausea / chemically induced. Neutropenia / chemically induced. Platelet Count. Prospective Studies. Rituximab. Thrombocytopenia / chemically induced. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621406.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; AYI8EX34EU / Creatinine; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


41. Vanhentenrijk V, Vanden Bempt I, Dierickx D, Verhoef G, Wlodarska I, De Wolf-Peeters C: Relationship between classic Hodgkin lymphoma and overlapping large cell lymphoma investigated by comparative expressed sequence hybridization expression profiling. J Pathol; 2006 Oct;210(2):155-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between classic Hodgkin lymphoma and overlapping large cell lymphoma investigated by comparative expressed sequence hybridization expression profiling.
  • There is a diagnostic grey zone between classic Hodgkin lymphoma (cHL) and some non-Hodgkin lymphoma (NHL), including primary mediastinal B cell lymphoma, diffuse large B cell lymphoma, and anaplastic large cell lymphoma.
  • Using this approach, we identified a unique expression profile for all lymphoma types investigated.
  • Moreover, anaplastic lymphoma kinase (ALK)-negative ALCL clustered in a separate branch together with ALCL-like HL.
  • Thus, analysing the neoplastic cells concurrently with their microenvironment, ALK-negative ALCL and ALCL-like HL seem to be related to each other, while cHL constitutes a separate lymphoma entity.
  • [MeSH-major] Hodgkin Disease / genetics. Lymphoma, Large B-Cell, Diffuse / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Cluster Analysis. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Gene Expression Profiling / methods. Humans. Male. Middle Aged. Neoplasm Staging. Nucleic Acid Hybridization / methods

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16874743.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


42. Yasukawa K, Kato N, Kodama K, Hamasaka A, Hata H: The spectrum of cutaneous lymphomas in Japan: a study of 62 cases based on the World Health Organization Classification. J Cutan Pathol; 2006 Jul;33(7):487-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The relative incidence of malignant lymphoma subtypes differs according to geographic location.
  • This study investigated the epidemiology of cutaneous lymphoma subtypes in Japan and compared it with other countries.
  • METHODS: Sixty-two patients with cutaneous lymphoma attending the Department of Dermatology, National Hospital Organization Hokkaido Cancer Center were reviewed.
  • RESULTS: Of the 62 patients, 31 had primary cutaneous lymphoma (PCL) and 31 had secondary cutaneous lymphoma (SCL).
  • T- and natural killer (NK)-cell lymphoma accounted for 80% of PCL, of which, mycosis fungoides accounted for almost 35%.
  • Of the 31 patients with secondary cutaneous lymphoma, 17 patients (54%) had T- and NK-cell lymphoma, including nine adult T-cell leukemia/lymphoma patients, and 14 patients (46%) had B-cell lymphoma, including 11 diffuse large B-cell lymphoma patients.
  • The majority of patients with SCL and NK-cell lymphoma with primary or secondary skin lesions had a poor outcome.
  • CONCLUSIONS: PCL in this study showed a similar incidence to that of other institutions in Japan, while also demonstrating different frequencies from that of other countries, suggesting that the relative frequency of different PCL subtypes differ according to geographical location, similar to previous reports of systemic malignant lymphoma.
  • [MeSH-major] Lymphoma / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Incidence. Japan / epidemiology. Killer Cells, Natural / pathology. Leukemia, T-Cell / classification. Leukemia, T-Cell / epidemiology. Leukemia, T-Cell / pathology. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell, Cutaneous / classification. Lymphoma, T-Cell, Cutaneous / epidemiology. Lymphoma, T-Cell, Cutaneous / pathology. Male. Middle Aged. Mycosis Fungoides / classification. Mycosis Fungoides / epidemiology. Mycosis Fungoides / pathology. Retrospective Studies. Sezary Syndrome / classification. Sezary Syndrome / epidemiology. Sezary Syndrome / pathology. World Health Organization

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872471.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


43. Yoon DH, Choi DR, Ahn HJ, Kim S, Lee DH, Kim SW, Park BH, Yoon SO, Huh J, Lee SW, Suh C: Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP. Eur J Haematol; 2010 Aug;85(2):149-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP.
  • BACKGROUND: Assessment of tumor cell proliferation based on Ki-67 expression yielded conflicting prognostic predictions of patients with diffuse large B-cell lymphoma (DLBCL).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ki-67 Antigen / analysis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Cell Proliferation / drug effects. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Middle Aged. Prednisone / administration & dosage. Prognosis. Recurrence. Rituximab. Survival Analysis. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20477862.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Ki-67 Antigen; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


44. Di Raimondo F, Caruso L, Bonanno G, Naso P, Chiarenza A, Fiumara P, Bari A, Palumbo GA, Russo A, Giustolisi R: Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma? Ann Oncol; 2007 Feb;18(2):351-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma?
  • BACKGROUND: Endoscopic ultrasound (EUS) is considered the best technique for locoregional staging at diagnosis but its role in the follow-up of patients with gastric lymphoma after organ-conserving strategies has not been established.
  • DESIGN AND METHODS: We retrospectively evaluated 23 patients with primary gastric lymphoma treated with a stomach-conservative approach.
  • Sixteen of them were affected by MALT lymphoma and seven by diffuse large-B-cell lymphoma (DLBCL).
  • CONCLUSIONS: Although the length of follow-up cannot exclude late relapse, we think that in restaging and follow-up of gastric lymphoma, EUS seems not to be a reliable tool if it is abnormal and E-Bx still remains the gold standard.


45. Costa LJ, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Litzow MR, Ansell SM: Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. Br J Haematol; 2008 Oct;143(2):268-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
  • High-dose chemotherapy and haematopoietic stem cell (HSC) transplantation is considered standard therapy in patients with chemosensitive relapsed diffuse large B cell lymphoma (DLBCL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Large B-Cell, Diffuse / drug therapy. Transplantation Conditioning / adverse effects
  • [MeSH-minor] Adult. Aged. Body Weight. Carmustine / administration & dosage. Carmustine / adverse effects. Chi-Square Distribution. Cohort Studies. Cytarabine / administration & dosage. Cytarabine / adverse effects. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Length of Stay. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Melphalan / therapeutic use. Middle Aged. Mucositis / chemically induced. Recurrence. Risk. Statistics, Nonparametric. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18699848.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM regimen
  •  go-up   go-down


46. Kemp S, Gallagher G, Kabani S, Noonan V, O'Hara C: Oral non-Hodgkin's lymphoma: review of the literature and World Health Organization classification with reference to 40 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Feb;105(2):194-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral non-Hodgkin's lymphoma: review of the literature and World Health Organization classification with reference to 40 cases.
  • Forty cases of oral cavity non-Hodgkin's lymphoma (NHL) were evaluated for sex, age, location, clinical presentation, and World Health Organization (WHO) histological subtype.
  • Most of the lymphomas were of B cell lineage (98%), and the majority of these B cell lymphomas (58%) were histologically subtyped as diffuse large B cell lymphoma, which is considered to have an aggressive clinical course.
  • B and T cell specific markers were used to show lineage of the neoplastic cells.
  • [MeSH-major] International Classification of Diseases. Jaw Neoplasms / classification. Lymphoma, Non-Hodgkin / classification. Mouth Neoplasms / classification
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Rearrangement. Humans. Immunophenotyping. Lymphoma, B-Cell / classification. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Oral Health.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17604660.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


47. Micci F, Panagopoulos I, Tjønnfjord GE, Kolstad A, Delabie J, Beiske K, Heim S: Molecular cytogenetic characterization of t(14;19)(q32;p13), a new recurrent translocation in B cell malignancies. Virchows Arch; 2007 May;450(5):559-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic characterization of t(14;19)(q32;p13), a new recurrent translocation in B cell malignancies.
  • Translocations involving an immunoglobulin (IG) locus are a recurring theme in B cell neoplasia.
  • We present here three cases of B cell neoplasia that showed a t(14;19)(q32;p13) by karyotypic analysis.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 19. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Cytogenetics. Female. Genes, Immunoglobulin Heavy Chain. Humans. In Situ Hybridization, Fluorescence. Male. Mediastinal Neoplasms / genetics. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / therapy. Molecular Diagnostic Techniques. Spectral Karyotyping. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):287-90 [15101713.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):304-7 [12543779.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45 [16064138.001]
  • [Cites] Leukemia. 2004 Dec;18(12 ):2026-31 [15496980.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4135-9 [15483023.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jan;39(1):88-92 [14603446.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(18):6509-20 [12192049.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Sep;20(1):64-72 [9290956.001]
  • [Cites] Leukemia. 1993 Dec;7(12):2057-63 [8255106.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6414-8 [7604005.001]
  • [Cites] Pathology. 2005 Dec;37(6):493-507 [16373229.001]
  • [Cites] J Med Genet. 2005 Jul;42(7):558-64 [15994877.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92 (16):1355-7 [10944559.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3788-93 [11891328.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):459-64 [12688315.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Br J Haematol. 1994 Sep;88(1):88-93 [7803261.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2456-64 [9310498.001]
  • [Cites] Am J Clin Pathol. 1996 Apr;105(4):458-67 [8604688.001]
  • [Cites] J Cell Mol Med. 2002 Apr-Jun;6(2):151-9 [12169201.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):813-6 [12153169.001]
  • [Cites] Leukemia. 1994 Jan;8(1):72-80 [8289502.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):1987-92 [11733348.001]
  • [Cites] Semin Cancer Biol. 2004 Oct;14(5):317-9 [15288256.001]
  • (PMID = 17406891.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


48. Greisser J, Palmedo G, Sander C, Kutzner H, Kazakov DV, Roos M, Burg G, Kempf W: Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders. J Cutan Pathol; 2006 Nov;33(11):711-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders.
  • Monoclonal rearrangement of T-cell receptor genes (TCR) was reported in fresh frozen tissue of lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large-cell lymphoma (ALCL), but the diagnostic value of T-cell clonality in formalin-fixed, paraffin-embedded biopsies has so far not been assessed.
  • CONCLUSIONS: T-cell clonality can only be found in a minority (four of 18; 22%) of archival LyP specimens, even when employing a highly sensitive detection method and is thus of limited diagnostic value.
  • [MeSH-major] Antigens, CD30 / genetics. Gene Rearrangement, T-Lymphocyte / genetics. Lymphoproliferative Disorders / diagnosis. Receptors, Antigen, T-Cell / genetics. Skin Diseases, Genetic / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA / genetics. DNA Fragmentation. DNA, Neoplasm / genetics. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, T-Cell, Cutaneous / diagnosis. Lymphoma, T-Cell, Cutaneous / genetics. Lymphomatoid Papulosis / diagnosis. Lymphomatoid Papulosis / genetics. Male. Middle Aged. Skin Neoplasms / diagnosis. Skin Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083688.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / DNA, Neoplasm; 0 / Receptors, Antigen, T-Cell; 9007-49-2 / DNA
  •  go-up   go-down


49. Danev V, Genova S, Peshev Zh, Uchikov A, Batashki I: [Extranodal lymphomas of the gastrointestinal tract. Retrospective study of a six year period]. Khirurgiia (Sofiia); 2006;(2):5-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: For the mentioned period in the University Hospital "Sveti Georgi" are diagnosed 22 cases of extranodal Non-Hodgkin's lymphomas of the gastrointestinal tract; 9 (40.9%) of them originated from lymph nodes of Valdier, 1 (4.5%)--from parotid gland, 6 (27.3%)--from stomach, 4 (18.2%) from large intestine and 2 (9.1%) cases from the small intestine.
  • All the lymphomas were B-cells type; in 6 cases they are MALT lymphomas, and in the rest of the cases--diffuse large cell B-cell type Non-Hodgkin's lymphomas.
  • CONCLUSION: In our investigation all Non-Hodgkin's lymphomas of the gastrointestinal tract are of B-cell type.
  • Obviously their diagnosis is being late; probably because diffuse large cell B-cell type Non-Hodgkin's lymphomas are the predominant type.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18958902.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


50. Gan JL, Tang ZJ: [Clinical, endoscopic and pathological features of primary colorectal non-Hodgkin lymphoma: 24 cases report]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Nov;9(6):502-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical, endoscopic and pathological features of primary colorectal non-Hodgkin lymphoma: 24 cases report].
  • OBJECTIVE: To investigate the clinical, endoscopic and pathological features in primary colorectal non-Hodgkin lymphoma.
  • METHODS: Twenty-four cases of primary colorectal non-Hodgkin lymphoma were studied retrospectively.
  • The major pathology types were diffuse large B-cell lymphoma (11/24, 45.8%), intestinal T-cell lymphoma (8/24, 33.3%), and mucosa-associated lymphoid tissue lymphoma (MALT) (3/24, 12.5%).
  • CONCLUSION: The clinical features of primary colorectal non-Hodgkin's lymphoma have no specificity.
  • Diffuse large B-cell lymphoma and intestinal T-cell lymphoma are the main pathological types.
  • Comprehensive treatment of surgery and chemotherapy are effective methods for primary colorectal non-Hodgkin lymphoma.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Biopsy. Endoscopy. Female. Follow-Up Studies. Humans. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult


51. Schwartz LK, Kim MK, Coleman M, Lichtiger S, Chadburn A, Scherl E: Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol; 2006 Aug;4(8):1030-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease.
  • The risk of lymphoma in inflammatory bowel disease (IBD) has raised concerns regarding the lymphogenic potential of immunomodulatory therapy.
  • The link between immunosuppressive therapy and lymphoma risk is well established in patients with solid organ transplantations.
  • In this population, it is postulated that lymphocytes infected with the Epstein-Barr virus (EBV) proliferate unchecked due to impaired cell-mediated immunity.
  • In this report, we describe a case of EBV-positive non-Hodgkin's lymphoma arising in the ileal pouch of a patient with ulcerative colitis.
  • [MeSH-major] Anastomosis, Surgical. Colitis, Ulcerative / drug therapy. Colonic Pouches. Ileum / surgery. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclosporine / therapeutic use. Glucocorticoids / therapeutic use. Humans. Immunosuppressive Agents / therapeutic use. Male. Prednisone / therapeutic use

  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Gastroenterol Hepatol. 2007 Apr;5(4):521; author reply 521-2 [17445756.001]
  • [CommentOn] Clin Gastroenterol Hepatol. 2006 Aug;4(8):976-8 [16880119.001]
  • (PMID = 16854631.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone
  •  go-up   go-down


52. Chen SH, Yu KH, Lin TL, Chuang WY, Yen TC: Gallium scan-prompted skin biopsy revealed intravascular large B-cell lymphoma in a patient who presented with fever of unknown origin. Clin Nucl Med; 2009 May;34(5):318-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallium scan-prompted skin biopsy revealed intravascular large B-cell lymphoma in a patient who presented with fever of unknown origin.
  • [MeSH-major] Fever of Unknown Origin / radionuclide imaging. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Radiopharmaceuticals. Skin / pathology. Vascular Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Biopsy. Fluorodeoxyglucose F18. Gallium Radioisotopes. Humans. Male. Positron-Emission Tomography. Whole Body Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19387217.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


53. Dohi O, Hatori M, Ichinohasama R, Hosaka M, Hashimoto S, Kokubun S: Diffuse large B-cell lymphoma arising in a patient with neurofibromatosis type I and in a patient with neurofibromatosis type II. Tohoku J Exp Med; 2006 Feb;208(2):169-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma arising in a patient with neurofibromatosis type I and in a patient with neurofibromatosis type II.
  • We experienced two unusual cases of diffuse large B-cell lymphoma (DLBCL), which occurred in a patient with neurofibromatosis type I and a patient with neurofibromatosis type II.
  • B-cell lymphoma is one of the most common phenotypic subgroups of malignant lymphoma.
  • Flow cytometry revealed large-scale cells to be tumor cells, and they were positive for CD19, CD20, and CD22.
  • To the best of our knowledge, this is the first case of malignant lymphoma arising in a neurofibromatosis II patient.
  • As for neurofibromatosis I, there were some reports about occurrence of malignant lymphoma.
  • [MeSH-major] Lymphoma, B-Cell / complications. Lymphoma, Large B-Cell, Diffuse / complications. Neurofibromatosis 1 / complications. Neurofibromatosis 2 / complications. Skin Neoplasms / complications. Soft Tissue Neoplasms / complications
  • [MeSH-minor] Adult. Biomarkers, Tumor. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434841.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


54. Vranovsky A, Ladicka M, Lakota J: Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma. Neoplasma; 2008;55(2):107-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma.
  • A single center, retrospective analysis evaluating the outcome of patients with poor-risk aggressive non-Hodgkin's lymphoma (NHL) treated with high-dose chemotherapy and autologous stem cell transplantation (ASCT) as a part of firstline therapy.
  • Forty-seven patients younger than 65 years with diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), peripheral T-cell lymphoma (PTCL) or alk-negative anaplastic large cell lymphoma (ALCL) underwent ASCT between July 1997 and November 2005.
  • Our results confirm the efficacy of high-dose therapy with ASCT during first-line treatment of patients with poor-prognosis aggressive lymphoma, with substantial number of patients cured by using this treatment approach.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Prednisolone / therapeutic use. Retrospective Studies. Transplantation, Autologous. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18652043.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; DHAP protocol; MACOP-B regimen
  •  go-up   go-down


55. Casey R, Brennan P, Becker N, Boffetta P, Cocco P, Domingo-Domenech E, Foretova L, Nieters A, de Sanjosé S, Staines A, Vornanen M, Maynadié M: Influence of familial cancer history on lymphoid neoplasms risk validated in the large European case-control study epilymph. Eur J Cancer; 2006 Oct;42(15):2570-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of familial cancer history on lymphoid neoplasms risk validated in the large European case-control study epilymph.
  • Lymphomas have a potentially important familial component; large studies using recent classification systems are lacking.
  • A familial case of lymphoma increased the risk of Hodgkin's lymphoma (HL) (OR=3.4 [1.5-7.8]).
  • No increased risk was observed for diffuse large B-cell and follicular lymphomas.
  • Our study suggests familial aggregation of CLL with a family history of haematological cancer and of HL with a family history of lymphoma.
  • [MeSH-major] Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Europe / epidemiology. Female. Humans. Male. Middle Aged. Pedigree. Risk Factors. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928444.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


56. Kewalramani T, Zelenetz AD, Teruya-Feldstein J, Hamlin P, Yahalom J, Horwitz S, Nimer SD, Moskowitz CH: Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol; 2006 Jul;134(2):202-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.
  • Autologous transplantation (ASCT) is the standard of care for chemosensitive relapsed or primary refractory aggressive lymphoma, but little is known about its efficacy in the subset of patients with peripheral T-cell lymphoma (PTCL).
  • We undertook a retrospective review of patients with PTCL who underwent ASCT for relapsed or refractory disease after responding to second-line therapy, excluding patients with indolent histologies and those with anaplastic lymphoma kinase (ALK) expressing anaplastic large cell lymphoma.
  • The results of 24 patients with PTCL were compared with those of 86 consecutive patients with chemosensitive relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Epidemiologic Methods. Humans. Middle Aged. Prognosis. Recurrence. Transplantation Conditioning / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16759221.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


57. Deloose ST, Smit LA, Pals FT, Kersten MJ, van Noesel CJ, Pals ST: High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. Leukemia; 2005 May;19(5):851-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma.
  • Kaposi sarcoma-associated herpesvirus (KSHV) is known to be associated with two distinct lymphoproliferative disorders: primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD)/MCD-associated plasmablastic lymphoma.
  • Interestingly, all KSHV-positive cases belonged to a distinctive subgroup of 26 diffuse large B-cell lymphomas characterized by the expression of CD138 (syndecan-1) and plasmablastic/immunoblastic morphology.
  • [MeSH-major] Giant Lymph Node Hyperplasia / virology. HIV Infections / virology. Herpesviridae Infections / virology. Herpesvirus 8, Human. Lymphoma, AIDS-Related / virology. Lymphoma, Large B-Cell, Diffuse / virology. Sarcoma, Kaposi / virology
  • [MeSH-minor] Adult. Cohort Studies. Comorbidity. Female. Humans. Immunohistochemistry / methods. Immunophenotyping. Incidence. Male. Middle Aged. Netherlands / epidemiology


58. Gilaberte M, Gallardo F, Bellosillo B, Saballs P, Barranco C, Serrano S, Pujol RM: Recurrent and self-healing cutaneous monoclonal plasmablastic infiltrates in a patient with AIDS and Kaposi sarcoma. Br J Dermatol; 2005 Oct;153(4):828-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection with human immunodeficiency virus (HIV) increases the risk of developing non-Hodgkin lymphoma.
  • Plasmablastic lymphoma (PBL) is a rare variant of diffuse large cell lymphoma that often involves the oral cavity of HIV+ patients.
  • It is characterized by immunoblastic morphology and plasma cell phenotype.
  • Histology showed subcutaneous fat necrosis and clusters of atypical large plasma cells (plasmablastic cells).
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Epstein-Barr Virus Infections / complications. Herpesvirus 8, Human. Lymphoma, AIDS-Related / virology. Sarcoma, Kaposi / complications
  • [MeSH-minor] Adult. Humans. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / virology. Male. Neoplasm Regression, Spontaneous. Recurrence


59. Lai R, Rassidakis GZ, Lin Q, Atwell C, Medeiros LJ, Amin HM: Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma. Hum Pathol; 2005 Sep;36(9):939-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma.
  • In previous studies of anaplastic large cell lymphoma (ALCL), we showed that inhibition of Jak3 down-regulates activated/phosphorylated Stat3 (pStat3), decreases anaplastic lymphoma kinase (ALK) enzymatic activity, and induces cell-cycle arrest and apoptosis in ALK-positive ALCL.
  • Most likely, Jak3 collaborates with ALK in activating Stat3, leading to cell survival, cell-cycle progression, and tumor growth.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / enzymology. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Adolescent. Adult. Child. Enzyme Activation. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Janus Kinase 3. Male. Middle Aged. Phosphorylation. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16153455.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / JAK3 protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 2.7.10.2 / Janus Kinase 3
  •  go-up   go-down


60. Wolach O, Bairey O, Lahav M: Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore); 2010 Sep;89(5):308-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rituximab is a chimeric monoclonal antibody against CD20 that is used mainly for the treatment of CD20-positive lymphoma.
  • Four patients were treated for diffuse large B-cell lymphoma, and 2 patients for follicular lymphoma.
  • Data regarding populations at risk are not consistent, and in some instances are conflicting.Patients considered at increased risk of LON include patients after autologous stem cell transplantation, patients treated for acquired immunodeficiency syndrome (AIDS)-related lymphoma, and patients treated with purine analogues.
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Lung Diseases / chemically induced. Lung Diseases / epidemiology. Male. Middle Aged. Risk Factors. Rituximab. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20827108.001).
  • [ISSN] 1536-5964
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


61. Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J, Uyttebroeck A, Mortelmans L, De Wolf-Peeters C, Verhoef G: Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria. Leuk Lymphoma; 2007 Aug;48(8):1522-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria.
  • Until recently, response assessment in patients with lymphoma was primarily performed by computed tomography (CT).
  • Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is a more sensitive and specific imaging technique for the detection of residual disease in lymphoma, and Revised Integrated International Workshop Criteria (IWC + PET) were recently proposed by the members of the International Harmonization Project (IHP), which combine both imaging techniques.
  • We determined whether these new IWC + PET-criteria, can more accurately predict outcome compared to IWC-criteria in aggressive and indolent non-Hodgkin's lymphoma (NHL), and therefore correlated IWC and IWC + PET response with time-to-next-treatment (TNT) in 69 patients with NHL.
  • We demonstrated that IWC + PET-guidelines are highly recommended over IWC-guidelines for patients with potentially-curable and routinely FDG-avid lymphoma.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / radiography. Burkitt Lymphoma / radionuclide imaging. Humans. International Cooperation. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiography. Lymphoma, B-Cell / radionuclide imaging. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiography. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Middle Aged. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / pathology. Practice Guidelines as Topic. Predictive Value of Tests. Sensitivity and Specificity. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701583.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


62. Marinella MA: The nose knows cancer recurrence. South Med J; 2008 Sep;101(9):970
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Odors
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Humans. Necrosis. Neoplasm Recurrence, Local. Treatment Refusal

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18708967.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


63. Gołkowski F, Buziak-Bereza M, Barczyński M, Stefańska A, Wierzchowski W, Huszno B, Cichoń S: [A case of primary malignant lymphoma of thyroid in young man]. Przegl Lek; 2006;63(9):815-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary malignant lymphoma of thyroid in young man].
  • The aim of this study is to present a case of a 36-year old male with a rare thyroid malignancy--a primary thyroid lymphoma.
  • Pathological report of postoperative specimen allowed for the final diagnosis of a malignant lymphoma originating from non-Hodgkin B cells of the thyroid gland; diffuse large B-cell lymphoma (DLCL) according to WHO classification.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / surgery. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / surgery. Thyroidectomy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Prednisone / therapeutic use. Remission Induction. Thyroid Gland / pathology. Thyroid Gland / ultrasonography. Thyroxine / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17479878.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q51BO43MG4 / Thyroxine; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


64. Cerhan JR, Engels EA, Cozen W, Davis S, Severson RK, Morton LM, Gridley G, Hartge P, Linet M: Blood transfusion, anesthesia, surgery and risk of non-Hodgkin lymphoma in a population-based case-control study. Int J Cancer; 2008 Aug 15;123(4):888-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood transfusion, anesthesia, surgery and risk of non-Hodgkin lymphoma in a population-based case-control study.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Anesthesia.
  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • MedlinePlus Health Information. consumer health - Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2008 Wiley-Liss, Inc.
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1532-7 [16896045.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1295-300 [16835326.001]
  • [Cites] Transfus Med Rev. 2000 Jul;14(3):258-68 [10914420.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1180-95 [11222359.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):361-8 [11319177.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2015-23 [11932904.001]
  • [Cites] Am J Epidemiol. 2002 Apr 15;155(8):725-31 [11943690.001]
  • [Cites] Surg Endosc. 2003 Feb;17(2):242-6 [12399854.001]
  • [Cites] Epidemiol Rev. 2002;24(2):269-79 [12762097.001]
  • [Cites] J Bone Joint Surg Am. 2000 Apr;82(4):457-76 [10761937.001]
  • [Cites] Am J Epidemiol. 2003 Jun 1;157(11):1052 [12777369.001]
  • [Cites] Pediatrics. 2003 Jun;111(6 Pt 1):1343-50 [12777551.001]
  • [Cites] Acta Orthop Scand. 2003 Jun;74(3):351-60 [12899558.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):76-80 [15185346.001]
  • [Cites] Best Pract Res Clin Anaesthesiol. 2004 Sep;18(3):493-507 [15212341.001]
  • [Cites] Am J Epidemiol. 2004 Aug 15;160(4):325-30 [15286017.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1415-21 [15342441.001]
  • [Cites] Cancer. 1968 Jan;21(1):109-18 [5634841.001]
  • [Cites] Scand J Haematol. 1982 Jan;28(1):59-64 [7071517.001]
  • [Cites] J Bone Joint Surg Br. 1988 Aug;70(4):539-42 [3403594.001]
  • [Cites] Fundam Appl Toxicol. 1989 Aug;13(2):205-16 [2676672.001]
  • [Cites] Orthopedics. 1991 Feb;14(2):137-42 [2008381.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5477s-5478s [1394157.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5510s-5515s [1394165.001]
  • [Cites] Ann Intern Med. 1993 Jul 1;119(1):8-15 [8498768.001]
  • [Cites] Eur J Cancer. 1993;29A(15):2101-5 [8297647.001]
  • [Cites] Int J Cancer. 1994 Aug 1;58(3):366-8 [8050819.001]
  • [Cites] Surg Endosc. 1995 Jan;9(1):49-52 [7725214.001]
  • [Cites] Br J Cancer. 1996 May;73(9):1148-51 [8624279.001]
  • [Cites] Biomed Pharmacother. 1997;51(5):200-7 [9247016.001]
  • [Cites] Ann Intern Med. 1997 Sep 1;127(5):365-71 [9273827.001]
  • [Cites] Cancer Causes Control. 1998 Mar;9(2):183-7 [9578295.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1439-42 [9782033.001]
  • [Cites] Vox Sang. 1998;75(2):145-8 [9784669.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 18;90(22):1742-3 [9827530.001]
  • [Cites] Am J Surg. 1999 Jan;177(1):55-60 [10037309.001]
  • [Cites] Am J Epidemiol. 1999 Jun 15;149(12):1113-8 [10369505.001]
  • [Cites] Eur J Surg. 1999 Jun;165(6):528-34 [10433134.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1332-3 [10433627.001]
  • [Cites] Langenbecks Arch Surg. 2004 Nov;389(6):475-84 [15173946.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):934-7 [15824166.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1102-8 [16775166.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 18506687.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / CN / N01 PC067009; United States / NCI NIH HHS / PC / N02-PC-71105; United States / NCI NIH HHS / CN / N01 PC067009-025; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01 PC067010; United States / NCI NIH HHS / CA / K07 CA64220; United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01 PC067008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / Intramural NIH HHS / / ZIA CP010170-13; None / None / / N01 PC065064; United States / NCI NIH HHS / PC / N01 PC065064; United States / NCI NIH HHS / CA / R01 CA092153; United States / NCI NIH HHS / CA / R01 CA92153; United States / NCI NIH HHS / CA / P50 CA097274
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS547986; NLM/ PMC3913466
  •  go-up   go-down


65. Hansra D, Montague N, Stefanovic A, Akunyili I, Harzand A, Natkunam Y, de la Ossa M, Byrne GE, Lossos IS: Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics. Am J Clin Pathol; 2010 Nov;134(5):710-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics.
  • Plasmablastic lymphoma (PBL), initially characterized as an aggressive lymphoma arising in the jaw and oral mucosa in HIV-infected patients, was recently reported to occur with extraoral manifestations, heterogeneous histologic findings, and variable association with immunodeficiency states.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Mouth Neoplasms / pathology. Plasma Cells / pathology
  • [MeSH-minor] Adult. Child, Preschool. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / pathology. HIV Infections / complications. HIV Infections / pathology. Humans. Immunohistochemistry. In Situ Hybridization. Kaplan-Meier Estimate. Male. Middle Aged. Mouth Mucosa / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Pathol. 2011 Jun;135(6):977-8; author reply 978-9 [21571968.001]
  • (PMID = 20959653.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


66. Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W: Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation. Br J Dermatol; 2005 Jul;153(1):167-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
  • BACKGROUND: Primary cutaneous B-cell lymphomas (PCBCLs) are characterized by restriction to the skin and a variable but mostly favourable prognosis.
  • Since 1997 the recombinant, chimeric anti-CD20 antibody rituximab has been used in patients suffering from non-Hodgkin's B-cell lymphomas.
  • Different studies have shown that the effectiveness and safety in the treatment of patients with low-grade follicular lymphoma is comparable to or even higher than the standard CHOP chemotherapy.
  • PATIENTS/METHODS: Ten patients with PCBCL [eight with follicle centre cell lymphoma (FCCL), one with marginal zone lymphoma (MZL) and one with diffuse large B-cell lymphoma of the leg (DLBCL)] were treated by intravenous application of a chimeric antibody against the CD20 transmembrane antigen (rituximab) with a dosage of eight cycles, 375 mg m(-2) body surface, weekly.
  • As expected the B-cell count in peripheral blood was depressed in all patients after infusion.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / immunology. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Drug Evaluation. Humans. Male. Middle Aged. Rituximab. Treatment Outcome


67. Avilés A, Neri N, Delgado S, Pérez F, Nambo MJ, Cleto S, Talavera A, Huerta-Guzmán J: Residual disease after chemotherapy in aggressive malignant lymphoma: the role of radiotherapy. Med Oncol; 2005;22(4):383-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual disease after chemotherapy in aggressive malignant lymphoma: the role of radiotherapy.
  • Residual disease in patients with diffuse large B-cell lymphoma after intensive chemotherapy remains a problem.
  • One hundred and sixty-six patients with diagnosis of diffuse large B-cell lymphoma, high- or high-intermediate clinical risk, with residual disease (defined as tumor mass < 5 cm) were randomly assigned to received radiotherapy at the involved field, with 30 Gy delivered in 20 sessions or no radiation (control group).
  • We concluded that presence of residual mass after chemotherapy in patients with aggressive malignant lymphoma has a worse prognosis, and salvage radiotherapy improves outcome with mild toxicity.
  • [MeSH-major] Lymphoma, B-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Cyclophosphamide. Doxorubicin. Female. Humans. Male. Middle Aged. Neoplasm, Residual / radiotherapy. Prednisolone. Prognosis. Survival Analysis. Survival Rate. Vincristine

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Oncol. 1999;38(6):799-804 [10522771.001]
  • [Cites] Blood. 1999 Jul 15;94(2):429-33 [10397709.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1107-10 [11072169.001]
  • [Cites] Radiother Oncol. 1985 Feb;3(2):133-8 [3838590.001]
  • [Cites] Acta Oncol. 2000;39(4):485-9 [11041110.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):161-8 [10924986.001]
  • [Cites] Oncology. 2000 Apr;58(3):219-26 [10765124.001]
  • [Cites] Blood. 1999 Nov 15;94(10 ):3289-93 [10552937.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):17-22 [11163493.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1385-9 [15359637.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):989-95 [11697654.001]
  • [Cites] Cancer Treat Rev. 2003 Feb;29(1):11-9 [12633576.001]
  • [Cites] Ann Hematol. 2002 Jul;81(7):368-73 [12185505.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):743-9 [11395243.001]
  • [Cites] Radiother Oncol. 1998 Oct;49(1):1-7 [9886690.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 1;31(1):3-11 [7527799.001]
  • [Cites] Radiother Oncol. 2001 Mar;58(3):251-5 [11230885.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):799-803 [7525515.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):1074-84 [8164032.001]
  • (PMID = 16260856.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


68. Sawka CA, Shepherd FA, Franssen E, Brandwein J, Dotten DA, Routy JP, Walker IR, St-Louis J, Taylor M, Arts K, Crump M, Foote M: A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma. Biotechnol Annu Rev; 2005;11:381-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
  • Non-Hodgkin's lymphoma (NHL) remains an important complication of associated HIV infection despite advances in antiretroviral therapy (ART), and the optimum chemotherapy regimen for this disease remains to be defined.
  • Forty-seven patients were enrolled, most with diffuse large-cell or immunoblastic NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Bleomycin / adverse effects. Bleomycin / therapeutic use. CD4 Lymphocyte Count. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Etoposide / administration & dosage. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Injections, Intravenous. Injections, Subcutaneous. Male. Middle Aged. Prednisone / adverse effects. Prednisone / therapeutic use. Prospective Studies. Recombinant Proteins. Survival Analysis. Treatment Outcome. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216784.001).
  • [ISSN] 1387-2656
  • [Journal-full-title] Biotechnology annual review
  • [ISO-abbreviation] Biotechnol Annu Rev
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Recombinant Proteins; 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; VB0R961HZT / Prednisone; VACOP-B protocol
  •  go-up   go-down


69. Ioannou S, Vlahadami I, Voulgarelis M: Bone marrow necrosis and fat embolism syndrome presented as conus medullaris syndrome in a patient with primary mediastinal large B-cell lymphoma. Leuk Res; 2010 Jan;34(1):116-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow necrosis and fat embolism syndrome presented as conus medullaris syndrome in a patient with primary mediastinal large B-cell lymphoma.
  • [MeSH-major] Bone Marrow / pathology. Embolism, Fat / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / pathology. Spinal Cord Compression / pathology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Embolism.
  • Genetic Alliance. consumer health - Bone marrow necrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19540591.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


70. Papageorgiou ES, Tsirigotis P, Dimopoulos M, Pavlidis N, Fountzilas G, Papageorgiou S, Economopoulos T, Hellenic Cooperative Oncology Group: Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group. Eur J Haematol; 2005 Aug;75(2):124-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group.
  • To investigate the efficacy and toxicity of the combination of gemcitabine and vinorelbine in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBL), 22 patients with relapsed or refractory DLBL were treated with gemcitabine 1000 mg/m2 and vinorelbine 30 mg/m2 on days 1 and 8 every 3 wk for a maximum of six cycles.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Deoxycytidine / analogs & derivatives. Lymphoma, Large B-Cell, Diffuse / drug therapy. Salvage Therapy / methods. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell / drug therapy. Male. Middle Aged. Remission Induction. Survival Analysis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2005.
  • (PMID = 16000128.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


71. Smith BD, Smith GL, Cooper DL, Wilson LD: The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry. J Clin Oncol; 2005 May 20;23(15):3390-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry.
  • PURPOSE: Three classification and prognostic systems exist for primary cutaneous B-cell lymphoma (PCBCL).
  • Group IB included diffuse large B-cell histology involving favorable skin sites (head/neck, arm).
  • Group II included diffuse large B-cell histology involving unfavorable skin sites (trunk, legs, disseminated) or immunoblastic large B-cell histology involving favorable skin sites.
  • Group III included immunoblastic large B-cell histology involving unfavorable skin sites.
  • [MeSH-major] Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / pathology. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Age Distribution. Aged. Biopsy, Needle. Female. Humans. Immunohistochemistry. Incidence. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Probability. Prognosis. Proportional Hazards Models. Registries. Risk Assessment. SEER Program. Sensitivity and Specificity. Sex Distribution. Survival Analysis. World Health Organization

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Oct 1;23(28):7246-8 [16192622.001]
  • (PMID = 15908651.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM07205
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


72. Oschlies I, Salaverria I, Mahn F, Meinhardt A, Zimmermann M, Woessmann W, Burkhardt B, Gesk S, Krams M, Reiter A, Siebert R, Klapper W: Pediatric follicular lymphoma--a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma--Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica; 2010 Feb;95(2):253-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric follicular lymphoma--a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma--Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials.
  • Background Pediatric follicular lymphoma has recently been recognized as a novel variant of follicular lymphoma in the World Health Organization classification of lymphomas.
  • Given the rarity of the disease, histopathological and genetic data on this type of lymphoma are still scarce.
  • DESIGN AND METHODS: We analyzed 25 cases of pediatric follicular lymphoma (patients aged <or=18 years) by morphology, immunohistochemistry and interphase fluorescence in situ hybridization.
  • All patients analyzed were treated within Non-Hodgkin's Lymphoma--Berlin-Frankfurt-Münster (NHL-BFM) multicenter trials, and the cohort was representative of the German population.
  • RESULTS: The genetic hallmark of adult follicular lymphoma, t(14;18)(q32;q21), was not detectable in any of the pediatric cases, although BCL2 protein was expressed in 55% of the latter cases.
  • Patients with pediatric follicular lymphoma had long event-free survival and, in contrast to adult follicular lymphoma, the clinical course was not dominated by relapses.
  • A simultaneous diffuse large B-cell lymphoma was frequently detected at initial diagnosis in children but did not indicate an aggressive clinical course.
  • Conclusions Our data suggest that pediatric follicular lymphoma is a disease that differs from its adult counterpart both genetically and clinically.
  • [MeSH-major] Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cohort Studies. Cytogenetic Analysis. Female. Gene Expression. Humans. Immunohistochemistry. Infant. Lymphoma, Large B-Cell, Diffuse / diagnosis. Male. Proto-Oncogene Proteins c-bcl-2 / genetics. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Br J Haematol. 2008 Jun;142(2):166-78 [18492111.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2667-74 [15238420.001]
  • [Cites] Cancer. 1979 Apr;43(4):1216-24 [376087.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]
  • [Cites] Cancer. 1981 Nov 15;48(10):2223-35 [7028244.001]
  • [Cites] Mod Pathol. 1990 May;3(3):308-13 [2194214.001]
  • [Cites] Leukemia. 1992 Aug;6(8):761-5 [1640726.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):359-72 [7844597.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):220-3 [9792312.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1626-35 [10193956.001]
  • [Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122 Suppl:S98-109 [15690646.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):141-51 [16645199.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2426-33 [17485708.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1374-81 [18509088.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5165-9 [18838711.001]
  • [Cites] Int J Cancer. 2009 Feb 15;124(4):958-63 [19030176.001]
  • [Cites] Arch Pathol Lab Med. 2009 Jan;133(1):142-6 [19123728.001]
  • [Cites] Br J Haematol. 2008 Jul;142(3):329-47 [18537979.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1959-64 [11877266.001]
  • (PMID = 19679882.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  • [Other-IDs] NLM/ PMC2817028
  •  go-up   go-down


73. Bralić M, Stemberga V, Cuculić D, Coklo M, Bulić O, Grgurević E, Bosnar A: Primary non-Hodgkin's lymphoma of the humerus presenting as osteomyelitis. Coll Antropol; 2008 Oct;32 Suppl 2:229-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the humerus presenting as osteomyelitis.
  • We report a case of primary non-Hodgkin's lymphoma of the humerus that occurred in a 21-year-old male patient.
  • A biopsy was performed and the final pathologic diagnosis was a diffuse large B-cell lymphoma.
  • The patient was treated for lymphoma only with radiotherapy.
  • [MeSH-major] Bone Neoplasms / pathology. Humerus. Lymphoma, Large B-Cell, Diffuse / pathology. Osteomyelitis / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Diagnostic Errors. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Osteomyelitis.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138030.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


74. Hermann S, Rohrmann S, Linseisen J, Nieters A, Khan A, Gallo V, Overvad K, Tjønneland A, Raaschou-Nielsen O, Bergmann MM, Boeing H, Becker N, Kaaks R, Bueno-de-Mesquita HB, May AM, Vermeulen RC, Bingham S, Khaw KT, Key TJ, Travis RC, Trichopoulou A, Georgila C, Triantafylou D, Celentano E, Krogh V, Masala G, Tumino R, Agudo A, Altzibar JM, Ardanaz E, Martínez-García C, Suárez MV, Tormo MJ, Braaten T, Lund E, Manjer J, Zackrisson S, Hallmans G, Malmer B, Boffetta P, Brennan P, Slimani N, Vineis P, Riboli E: Level of education and the risk of lymphoma in the European prospective investigation into cancer and nutrition. J Cancer Res Clin Oncol; 2010 Jan;136(1):71-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Level of education and the risk of lymphoma in the European prospective investigation into cancer and nutrition.
  • We explored the association between education and the incidence of lymphoma in the prospective EPIC study.
  • MATERIALS AND METHODS: Within 3,567,410 person-years of follow-up, 1,319 lymphoma cases [1,253 non-Hodgkin lymphomas (NHL) and 66 Hodgkin lymphomas (HL)] were identified.
  • Cox proportional hazard regression was used to examine the association between highest educational level (primary school or less, technical/professional school, secondary school, university) and lymphoma risk.
  • RESULTS: Overall, no consistent associations between educational level and lymphoma risk were observed; however, associations were found for sub-groups of the cohort.
  • Concerning sub-classes of B-NHL, a positive association between education and risk of B cell chronic lymphatic leukaemia (BCLL) was observed only in women.
  • In both genders, the risk of diffuse large B cell lymphoma (DLBCL) was significantly lower for subjects with university degree (HR = 0.46, 95% CI = 0.27–0.79) versus lowest educational level.
  • CONCLUSION: We could not confirm an overall consistent association of education and risk of HL or NHL in this large prospective study; although, education was positively related to the incidence of BCLL and B-NHL (in women) but inversely to incidence of DLBCL.
  • Due to limited number of cases in sub-classes and the large number of comparisons, the possibility of chance findings can not be excluded.
  • [MeSH-major] Educational Status. Hodgkin Disease / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Diet. Europe / epidemiology. Female. Humans. Incidence. Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Male. Middle Aged. Prevalence. Proportional Hazards Models. Prospective Studies. Risk Assessment / statistics & numerical data. Risk Factors. Sex Factors. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):811-6 [16160698.001]
  • [Cites] Cancer. 1981 Dec 1;48(11):2547-54 [7296505.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:40-61 [17405120.001]
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):813-20 [11714109.001]
  • [Cites] Public Health Nutr. 2002 Dec;5(6B):1113-24 [12639222.001]
  • [Cites] J Epidemiol Community Health. 2004 Oct;58(10):858-61 [15365113.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Am J Public Health. 2000 Aug;90(8):1277-81 [10937009.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):779-86 [15159310.001]
  • [Cites] J Natl Cancer Inst. 1982 Aug;69(2):387-92 [6955544.001]
  • [Cites] Int J Cancer. 1989 Apr 15;43(4):554-9 [2703267.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(2):391-401 [17134891.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:1-39 [17405121.001]
  • [Cites] Int J Epidemiol. 1991 Jun;20(2):354-61 [1917234.001]
  • [Cites] Int J Cancer. 1991 Feb 1;47(3):352-7 [1993542.001]
  • [Cites] Int J Cancer. 1990 Mar 15;45(3):423-7 [2307531.001]
  • (PMID = 19582474.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0401527
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


75. Nakamura S, Matsumoto T, Ye H, Nakamura S, Suekane H, Matsumoto H, Yao T, Tsuneyoshi M, Du MQ, Iida M: Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a clinicopathologic and molecular study with reference to antibiotic treatment. Cancer; 2006 Dec 15;107(12):2770-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a clinicopathologic and molecular study with reference to antibiotic treatment.
  • BACKGROUND: The majority of gastric mucosa-associated lymphoid tissue (MALT) lymphoma develops in Helicobacter pylori-associated chronic gastritis.
  • Little is still known regarding the clinicopathologic features of gastric MALT lymphoma not associated with H. pylori infection.
  • METHODS: One hundred thirty-seven patients with gastric MALT lymphoma, in whom H. pylori status was evaluated using at least both serology and histology, were enrolled.
  • RESULTS: In cases without diffuse large B-cell lymphoma (DLBCL) component, H. pylori-negative lymphomas located more frequently in the proximal stomach (70%), less frequently appeared as superficial type (40%), and frequently invaded the submucosa or beyond (70%).
  • CONCLUSIONS: H. pylori-negative gastric MALT lymphoma is characterized by frequent t(11;18)(q21;q21).
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Helicobacter pylori / isolation & purification. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 17099876.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


76. Liu YH, Xu FP, Zhuang HG, Lai KC, Xie D, Luo DL, Li L, Luo XL, Xu J, Zhang MH, Zhang F, Li HM: Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients. Hum Pathol; 2008 Jun;39(6):875-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
  • Diffuse large B-cell lymphoma (DLBCL) can be subdivided into prognostically significant groups with germinal center B-cell-like (GCB), activated B-cell-like (ABC), and type 3 groups.
  • [MeSH-major] B-Lymphocytes / immunology. Cell Transformation, Neoplastic. Germinal Center / pathology. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Proliferation. Child. Child, Preschool. China. Female. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Tissue Array Analysis


77. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK: FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood; 2006 Oct 15;108(8):2720-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.
  • The precise mechanism of rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) therapy in diffuse large B-cell lymphoma (DLBCL) is not fully elucidated.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / genetics. Polymorphism, Single Nucleotide. Receptors, IgG / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Alleles. Antibodies, Monoclonal, Murine-Derived. Base Sequence. Combined Modality Therapy. Cyclophosphamide / administration & dosage. DNA, Neoplasm / genetics. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Retrospective Studies. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16609067.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / DNA, Neoplasm; 0 / FCGR2A protein, human; 0 / FCGR3A protein, human; 0 / Receptors, IgG; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


78. Maruyama D, Watanabe T, Beppu Y, Kobayashi Y, Kim SW, Tanimoto K, Makimoto A, Kagami Y, Terauchi T, Matsuno Y, Tobinai K: Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study. Jpn J Clin Oncol; 2007 Mar;37(3):216-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study.
  • BACKGROUND: The incidence of primary bone lymphoma (PBL) is so rare that many of its aspects remain unknown.
  • Although 19 (68%) patients had diffuse large B-cell lymphoma (DLBCL), other histopathological subtypes (three B-lymphoblastic lymphoma, two anaplastic large cell lymphoma, two indolent B-cell lymphoma, one NK/T-cell lymphoma (NTCL) and one Hodgkin lymphoma) were also included.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Hodgkin Disease / pathology. Humans. Lymphoma, B-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472971.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


79. Wöhrer S, Bartsch R, Hejna M, Drach J, Raderer M: Routine application of the proton-pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapy. Scand J Gastroenterol; 2005 Oct;40(10):1222-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine application of the proton-pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapy.
  • MATERIAL AND METHODS: All patients undergoing chemotherapy for gastric lymphoma at our institution were prophylactically given oral pantoprazole (2x40 mg) for the duration of chemotherapy.
  • RESULTS: A total of 82 patients (median age 69 years, range 33-93) received chemotherapy for gastric lymphoma: 51 had diffuse large B-cell lymphoma (DLBCL), 24 had mucosa-associated lymphoid tissue (MALT) lymphoma and 7 had DLBCL+MALT lymphoma.
  • In the absence of randomized trials, routine application of oral pantoprazole in patients given chemotherapy for gastric lymphoma, especially DLBCL, appears to be a reasonable approach.
  • [MeSH-major] Anti-Ulcer Agents / therapeutic use. Benzimidazoles / therapeutic use. Lymphoma, B-Cell / drug therapy. Omeprazole / analogs & derivatives. Proton Pump Inhibitors. Stomach Neoplasms / drug therapy. Sulfoxides / therapeutic use
  • [MeSH-minor] 2-Pyridinylmethylsulfinylbenzimidazoles. Administration, Oral. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Follow-Up Studies. Humans. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / pathology. Middle Aged. Mitoxantrone / administration & dosage. Neoplasm Staging. Patient Compliance. Prednisone / administration & dosage. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. PANTOPRAZOLE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16265779.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Anti-Ulcer Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Benzimidazoles; 0 / Proton Pump Inhibitors; 0 / Sulfoxides; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; D8TST4O562 / pantoprazole; KG60484QX9 / Omeprazole; VB0R961HZT / Prednisone
  •  go-up   go-down


80. Yeh YM, Chang KC, Chen YP, Kao LY, Tsai HP, Ho CL, Wang JR, Jones D, Chen TY: Large B cell lymphoma presenting initially in bone marrow, liver and spleen: an aggressive entity associated frequently with haemophagocytic syndrome. Histopathology; 2010 Dec;57(6):785-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large B cell lymphoma presenting initially in bone marrow, liver and spleen: an aggressive entity associated frequently with haemophagocytic syndrome.
  • AIMS: To describe diffuse large B cell lymphoma (DLBCL) presenting initially in bone marrow, liver and spleen (BLS-type) without lymphadenopathy.
  • Usually presenting with fever and haemophagocytic syndrome suggesting infection and complicating timely diagnosis, bone marrow examination showed patchy and interstitial infiltration of large tumour cells without sinusoidal involvement.
  • All cases had a high Ki-67 index (≥90%), commonly a non-germinal centre/activated B cell immunophenotype and were negative for Epstein-Barr virus and human herpesvirus 6 and 8.
  • High-dose chemotherapy with haematopoietic stem cell transplantation prolonged survival in one patient.
  • CONCLUSIONS: Although it shares with intravascular LBCL a subtle presentation and an aggressive clinical course, this primary BLS large cell lymphoma variant is distinguished by lacking an intravascular component and having different cytogenetic findings.
  • [MeSH-major] Bone Marrow / pathology. Liver / pathology. Lymphohistiocytosis, Hemophagocytic / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Spleen / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Chromosomes, Human, Pair 14 / genetics. Cytogenetics. Female. Humans. Immunohistochemistry. In Situ Hybridization. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Limited.
  • (PMID = 21166693.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


81. Takakuwa T, Miyauchi A, Aozasa K: Aberrant somatic hypermutations in thyroid lymphomas. Leuk Res; 2009 May;33(5):649-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine a possible role of aberrant somatic hypermutation (ASHM) in the pathogenesis of thyroid lymphoma (TL), mutational status of genes affected by ASHM, including c-MYC, PIM-1, PAX-5 and RhoH/TTF, was analyzed.
  • Tumor specimens from 33 patients with thyroid B-cell lymphoma and 14 with chronic lymphocytic thyroiditis (CLTH), an autoimmune thyroiditis known to provide a basis for TL development, was examined.
  • Occurrence of ASHM in PIM-1, RhoH/TTF, and c-MYC was a constant finding in follicular lymphoma (FL) (all of 11 cases) but not so frequent in diffuse large B-cell lymphoma (DLBCL) (4 (33.3%) of 12 cases) and Marginal zone B-cell lymphoma (MZBCL) (1 (10.0%) of 10 cases).
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics. Mutation. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19019431.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


82. Yoshioka T, Miura I, Kume M, Takahashi N, Okamoto M, Ichinohasama R, Yoshino T, Yamaguchi M, Hirokawa M, Sawada K, Nakamura S: Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival. Genes Chromosomes Cancer; 2005 Feb;42(2):149-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival.
  • De novo CD5-positive diffuse large B-cell lymphoma (CD5(+)DLBCL) is regarded as a different clinicopathological entity from CD5-negative DLBCL (CD5(-)DLBCL) and mantle cell lymphoma (MCL).
  • [MeSH-major] Antigens, CD5 / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 8 / genetics. Cytogenetics / methods. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Breakage / genetics. Chromosome Deletion. Female. Gene Amplification / genetics. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15543600.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5
  •  go-up   go-down


83. Cady FM, O'Neill BP, Law ME, Decker PA, Kurtz DM, Giannini C, Porter AB, Kurtin PJ, Johnston PB, Dogan A, Remstein ED: Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol; 2008 Oct 10;26(29):4814-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.
  • PURPOSE: Primary CNS lymphoma (PCNSL) is an aggressive lymphoma but clinically validated biologic markers that can predict natural history to tailor treatment according to risk are lacking.
  • Herein we determined the prevalence and survival impact of del(6)(q22) and BCL6, immunoglobulin heavy chain (IGH), and MYC gene rearrangements in a large PCNSL cohort treated in a single center.
  • Unlike systemic diffuse large B-cell lymphoma, del(6)(q22) is common and IGH translocations are infrequent and usually involve BCL6 rather than BCL2, suggesting a distinct pathogenesis.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2006 Aug;65(8):776-82 [16896311.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):737-41 [12591717.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):447-51 [12640061.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):487-93 [12657933.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):164-9 [12802586.001]
  • [Cites] Cerebrovasc Dis. 2004;17(2-3):224-7 [14707426.001]
  • [Cites] Cell. 2004 Jun 11;117(6):699-711 [15186772.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]
  • [Cites] Blood. 1994 Apr 1;83(7):1757-9 [8142643.001]
  • [Cites] Blood. 1994 May 1;83(9):2423-7 [8167331.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Nov;7(11):833-46 [17057753.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1546-53 [17122510.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5711-5 [17116938.001]
  • [Cites] Blood. 1995 May 15;85(10):2877-84 [7742550.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):615-20 [9635710.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):123-33 [10337996.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1507-13 [15735126.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2233-9 [15800313.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3179-82 [16101124.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5718-27 [16009945.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2466-72 [16240449.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1281-8 [16525183.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2332-43 [17625604.001]
  • [Cites] Blood. 2008 Jan 1;111(1):292-301 [17720884.001]
  • [Cites] Leukemia. 2008 Feb;22(2):400-5 [17989719.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1268-72 [17989713.001]
  • [Cites] Nat Rev Immunol. 2005 Jan;5(1):43-57 [15630428.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1445-51 [10550299.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1386-92 [10555007.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):261-6 [10659013.001]
  • [Cites] Brain Pathol. 2000 Jan;10(1):73-84 [10668897.001]
  • [Cites] Neurosurgery. 2000 Aug;47(2):454-6; discussion 456-7 [10942021.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Mar;125(2):147-50 [11369058.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Br J Haematol. 2002 May;117(2):322-32 [11972514.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Oct;61(10):926-33 [12387458.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):323-31 [12559880.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1383-97 [8055462.001]
  • (PMID = 18645192.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA15083; United States / NCI NIH HHS / CA / P50 CA108961
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins
  • [Other-IDs] NLM/ PMC2653136
  •  go-up   go-down


84. Gutiérrez A, Martínez-Serra J, Barceló B, Sampol A, Viñas L, González G, Bea MD, Amat JC, Martín J, Ramos R, Bautista A, Forteza-Rey J, Rodríguez J, Besalduch J: Prognostic value of serum CA125 levels in diffuse large B-cell lymphoma: potential role of a new sex- and age-adjusted reference value. Int J Lab Hematol; 2010 Dec;32(6 Pt 2):582-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of serum CA125 levels in diffuse large B-cell lymphoma: potential role of a new sex- and age-adjusted reference value.
  • CA125, a tumor marker normally used to follow the clinical course of ovarian cancer, also may have a role in lymphoma.
  • We aim to study the prognostic value of serum CA125 (sCA125) levels in diffuse large B-cell lymphoma (DLBCL), considering the influence of age and sex on sCA125 levels.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Reference Values. Retrospective Studies. Sex Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20201996.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


85. Belousova IE, Vanecek T, Skreg SV, Rodionov AN, Samtsov AV, Kazakov DV: Unusual clinicopathological presentation of primary cutaneous diffuse large B-cell lymphoma, leg type, with multiple nodules and widespread garland-like lesions. Am J Dermatopathol; 2009 Jun;31(4):370-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual clinicopathological presentation of primary cutaneous diffuse large B-cell lymphoma, leg type, with multiple nodules and widespread garland-like lesions.
  • We present a case of primary cutaneous diffuse large B-cell lymphoma, leg type, with an unusual clinical picture.
  • Histological examination of a nodule revealed a diffuse nonepidermotropic infiltrate mainly composed of large blast cells with features of immunoblasts and centroblasts and spindle cells seen at the periphery of the infiltrate.
  • Histological examination of a garland-like lesion showed perivascular infiltrates composed predominantly of small lymphocytes admixed with only occasional large blasts.
  • Widespread garland-like lesions are not a typical feature of primary cutaneous diffuse large B-cell lymphoma.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Skin / pathology. Skin Neoplasms / genetics. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Base Sequence. Biopsy. Gene Rearrangement. Genes, Immunoglobulin Heavy Chain / genetics. Humans. Male. Phenotype

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461242.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Fuzellier JF, Saade YA, Torossian PF, Baehrel B: [Primary cardiac lymphoma: diagnosis and treatment. Report of 6 cases and review of the literature]. Arch Mal Coeur Vaiss; 2005 Sep;98(9):875-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cardiac lymphoma: diagnosis and treatment. Report of 6 cases and review of the literature].
  • Primary cardiac lymphoma (PCL) is the rarest primary cardiac tumour and carries a poor prognosis.
  • A diffuse large cell type B lymphoma was found in 5 patients and an anaplastic lymphoma in 1 patient.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cardiac Tamponade / etiology. Female. Heart Failure / etiology. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16231573.001).
  • [ISSN] 0003-9683
  • [Journal-full-title] Archives des maladies du coeur et des vaisseaux
  • [ISO-abbreviation] Arch Mal Coeur Vaiss
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


87. Burcheri S, Arcaini L: A paraumbilical lymphomatous mass. Eur J Haematol; 2006 Aug;77(2):180
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Humans. Male. Prednisone / administration & dosage. Remission Induction. Umbilicus. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856915.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


88. Paydas S, Ergin M, Erdogan S, Seydaoglu G: Cyclooxygenase-2 expression in non-Hodgkin's lymphomas. Leuk Lymphoma; 2007 Feb;48(2):389-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In histological terms, 60 cases (33%) had low grade and 117 (67%) had aggressive lymphoma.
  • [MeSH-major] Cyclooxygenase 2 / metabolism. Lymphoma, Large B-Cell, Diffuse / enzymology. Lymphoma, Mantle-Cell / enzymology. Lymphoma, Non-Hodgkin / enzymology. Lymphoma, T-Cell, Peripheral / enzymology. Membrane Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325901.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


89. Jardin F, Jais JP, Molina TJ, Parmentier F, Picquenot JM, Ruminy P, Tilly H, Bastard C, Salles GA, Feugier P, Thieblemont C, Gisselbrecht C, de Reynies A, Coiffier B, Haioun C, Leroy K: Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood; 2010 Aug 19;116(7):1092-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study.
  • Genomic alterations play a crucial role in the development and progression of diffuse large B-cell lymphomas (DLBCLs).
  • Losses of TP53 and CDKN2A, observed in 8% and 35% of patients, respectively, were significantly associated with a shorter survival after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment, independently of the International Prognostic Index and of the cell of origin.
  • These patients predominantly had an activated B-cell profile and showed a specific gene expression signature, characterized by dysregulation of the RB/E2F pathway, activation of cellular metabolism, and decreased immune and inflammatory responses.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Gene Expression Profiling. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prognosis. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-myc / genetics. Proto-Oncogene Proteins c-rel / genetics. Retinoblastoma Protein / genetics. Rituximab. Sequence Deletion. Tumor Suppressor Protein p53 / genetics. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20435884.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc; 0 / Proto-Oncogene Proteins c-rel; 0 / Retinoblastoma Protein; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


90. Sissolak G, Juritz J, Sissolak D, Wood L, Jacobs P: Lymphoma--emerging realities in sub-Saharan Africa. Transfus Apher Sci; 2010 Apr;42(2):141-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma--emerging realities in sub-Saharan Africa.
  • Substantial geographical differences exist for Hodgkin and other lymphoproliferative disorders with these having previously been documented in a report from the lymphoma reclassification project.
  • Median age was 55.2 years 61% were males, 10% had Hodgkin lymphoma and, overall, constitutional symptoms were present in 20%.
  • Median survival in hairy cell leukaemia (n=14), chronic lymphocytic leukaemia-small lymphocytic lymphoma (n=103), Hodgkin (n=41) and follicular lymphoma (n=59) was not reached at the time of analysis and exceeded 36 months.
  • This was followed by 32 months for those with mantle cell (n=7), splenic (n=2) and extranodal marginal cell (n=11), 24 months for T-cell lymphomas (n=24), 20 months for diffuse large B-cell variants (n=88) but only 12 months for the aggressive tumours exemplified by Burkitt (n=7) and lymphoblastic subtypes (n=6).
  • Overall survival at 3 years in each category was compared to the curve for the entire cohort and was 100% in hairy cell leukaemia receiving two chlorodeoxyadenosine and greater than 88% in Hodgkin lymphoma treated according to the German study group protocols (p=0.0004).
  • Corresponding figures for chronic lymphocytic leukaemia-small lymphocytic lymphoma were 82% (p=0.0006), follicular lymphoma 71% (p=0.060), peripheral T-cell lymphoma 43% (p=0.0156), diffuse large B-cell lymphoma 39% (p<0.0001), aggressive tumours 25% (p=0.0002) and for the indolent categories including mantle cell, splenic and extra nodal marginal cell lymphomas 22% (p=0.2023).
  • [MeSH-major] Lymphoma
  • [MeSH-minor] Adolescent. Adult. Africa South of the Sahara / epidemiology. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010. Published by Elsevier Ltd.
  • (PMID = 20149748.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


91. Alvarez CA, Rodriguez BI, Perez LA: Primary diffuse large B-cell lymphoma of the prostate in a young patient. Int Braz J Urol; 2006 Jan-Feb;32(1):64-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary diffuse large B-cell lymphoma of the prostate in a young patient.
  • We report a primary lymphoma of the prostate, which arose in a 29-year-old man with hematuria.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519830.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


92. Yi JH, Kim SJ, Choi JY, Ko YH, Kim BT, Kim WS: 18F-FDG uptake and its clinical relevance in primary gastric lymphoma. Hematol Oncol; 2010 Jun;28(2):57-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG uptake and its clinical relevance in primary gastric lymphoma.
  • We studied the clinical relevance of (18)F-fluorodeoxyglucose ((18)F-FDG) uptake in patients with primary gastric lymphoma underwent positron emission tomography (PET)/ computed tomography (CT) scan.
  • Forty-two patients with primary gastric lymphoma were analysed: 32 diffuse large B-cell lymphomas (DLBCL) and 10 extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue (MALT lymphomas).
  • All of these gastric lesions were grossly and pathologically benign lesions without evidence of lymphoma cells.
  • In conclusion, PET/CT scan can be used in staging patients with primary gastric lymphoma; however, the residual (18)F-FDG uptake observed during follow-up should be interpreted cautiously and should be combined with endoscopy and multiple biopsies of the stomach.
  • [MeSH-major] Fluorine Radioisotopes. Fluorodeoxyglucose F18. Lymphoma, B-Cell, Marginal Zone / radionuclide imaging. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals. Stomach Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Biopsy. Diagnosis, Differential. Female. Gastric Mucosa / pathology. Gastric Mucosa / radionuclide imaging. Gastroscopy. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasm Staging. Prognosis. Stomach Ulcer / radionuclide imaging. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 John Wiley & Sons, Ltd.
  • (PMID = 19593742.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


93. Schrepfer T, Haerle SK, Strobel K, Schaefer N, Hälg RA, Huber GF: The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas. Laryngoscope; 2010 May;120(5):937-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/HYPOTHESIS: Using a retrospective approach, the aim of this study was to confirm the previously described value of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) in patients with primary extranodal lymphoma of the head and neck region.
  • METHODS: Twenty-six patients with a primary extranodal head and neck lymphoma (22 diffuse large B-cell lymphoma, one Hodgkin's lymphoma, three malignant T-cell lymphomas) were included.
  • It also has application as an instrument for evaluation of follow-up and response to therapy in patients suffering from primary extranodal lymphoma and for detection of secondary malignancies.
  • [MeSH-major] Blood Glucose / metabolism. Hodgkin Disease / radionuclide imaging. Image Processing, Computer-Assisted. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radionuclide imaging. Otorhinolaryngologic Neoplasms / pathology. Otorhinolaryngologic Neoplasms / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radionuclide imaging. Adult. Aged. Aged, 80 and over. Cecal Neoplasms / mortality. Cecal Neoplasms / pathology. Cecal Neoplasms / radionuclide imaging. Female. Fluorodeoxyglucose F18. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / radionuclide imaging. Radiopharmaceuticals. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Blood Sugar.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422687.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


94. Omoti CE, Halim NK: Adult lymphomas in Edo state, Niger Delta region of Nigeria--clinicopathological profile of 205 cases. Clin Lab Haematol; 2005 Oct;27(5):302-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult lymphomas in Edo state, Niger Delta region of Nigeria--clinicopathological profile of 205 cases.
  • Non-Hodgkin's lymphoma (NHL) occurred predominantly in young adults (20-39 years).
  • The intermediate grade NHL (41.2%) formed the largest group of which diffuse large cell lymphoma (DLCL) was the most commonly observed histopathologic type followed by the large cell immunoblastic type.
  • [MeSH-major] Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Female. Hematologic Tests. Hodgkin Disease / diagnosis. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Humans. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Neoplasm Staging. Nigeria / epidemiology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178909.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Johnston A, Bouafia-Sauvy F, Broussais-Guillaumot F, Michallet AS, Traullé C, Salles G, Coiffier B: Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study. Leuk Lymphoma; 2010 Mar;51(3):399-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study.
  • The role of rituximab retreatment in relapsed B-cell lymphoma is not well known.
  • We undertook a single center retrospective cohort study to investigate the efficacy of retreatment with rituximab with or without chemotherapy in patients with relapsed and refractory B-cell lymphomas.
  • We only included patients treated first-line and in first progression; 178 patients were included in the study, of whom 29% had diffuse large B-cell lymphoma (DLBCL) and 28% had follicular lymphoma (FL).
  • In conclusion, retreatment with rituximab, with or without chemotherapy, yields a high overall response rate in patients with relapsed and refractory B-cell lymphomas.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Case-Control Studies. Disease Progression. Disease-Free Survival. Female. Humans. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / pathology. Male. Middle Aged. Recurrence. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 Mar;51(3):355-6 [20148756.001]
  • (PMID = 20038227.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


96. Pelosini M, Focosi D, Rita F, Galimberti S, Caracciolo F, Benedetti E, Papineschi F, Petrini M: Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature. Ann Hematol; 2008 May;87(5):405-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Immunosuppressive Agents / adverse effects. Leukoencephalopathy, Progressive Multifocal / immunology. Lymphoma, Follicular / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antiviral Agents / therapeutic use. Fatal Outcome. Female. Humans. Immunocompromised Host. JC Virus / pathogenicity. Male. Middle Aged. Rituximab

  • Genetic Alliance. consumer health - Progressive multifocal leukoencephalopathy.
  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064459.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antiviral Agents; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 61
  •  go-up   go-down


97. Cheng J, Tu P, Shi QL, Zhou HB, Zhou ZY, Zhao YC, Ma HH, Zhou XJ: [Primary diffuse large B-cell lymphoma of central nervous system belongs to activated B-cell-like subgroup: a study of 47 cases]. Zhonghua Bing Li Xue Za Zhi; 2008 Jun;37(6):384-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary diffuse large B-cell lymphoma of central nervous system belongs to activated B-cell-like subgroup: a study of 47 cases].
  • OBJECTIVE: To investigate the histogenetic origin of primary central nervous system diffuse large B-cell lymphoma (DLBCL) with respect to the stage of B-cell differentiation, and identification of the relevant prognostic markers.
  • Among the 47 patients, 43 cases (91.5%) showed an activated B-cell-like (ABC) phenotype: 21 (44.7%) were bcl-6+ and MUM-1+, suggesting an "activated germinal center (GC) B-cell-like" in origin; 22 (46.8%) were exclusively MUM-1+, suggesting an "activated non-GCB" in origin.
  • CONCLUSIONS: Most primary central nervous system DLBCL are shown belonging to the ABC subgroup, suggesting that primary central nervous system DLBCL is quite similar to a DLBCL subset, which is derived from late GC to early post-GC B cell.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. B-Lymphocytes / pathology. Biomarkers, Tumor / analysis. Central Nervous System. Female. Humans. Male. Middle Aged. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031717.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


98. Mourad WA, Al Thani S, Tbakhi A, Al Omari M, Khafaga Y, Shoukri M, El Weshi A, Al Shabana M, Ezzat A: Morphologic, immunphenotypic and clinical discriminators between T-cell/histiocyte-rich large B-cell lymphoma and lymphocyte-predominant Hodgkin lymphoma. Hematol Oncol Stem Cell Ther; 2008 Jan-Mar;1(1):22-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic, immunphenotypic and clinical discriminators between T-cell/histiocyte-rich large B-cell lymphoma and lymphocyte-predominant Hodgkin lymphoma.
  • BACKGROUND: Features of T-cell/histiocyte rich large B-cell lymphoma (THRLBCL) overlap with those of lymphocyte predominant Hodgkin lymphoma (LPHL).
  • METHODS: Cases of THRLBCL and LPHL were blindly reviewed and studied for histological pattern (nodular vs. diffuse), nuclear features and pattern of expression of CD20, CD30, CD57, epithelial membrane antigen (EMA) and Epstein-Barr virus (EBV).
  • A score encompassing diffuse histology, high nuclear grade, CD20 single-cell pattern, CD30+, CD57-, EMA-, and EBV+ was estimated for the diagnosis of TCHRLBCL.
  • TCHRLBCL and LPHL, respectively, showed diffuse histology, 90% vs. 4% (P = 0.001), single CD20+ cells, 93% vs. 3.5% (P = 0.00004), CD30+ cells, 30% vs. 0% (P = 0.01), CD57+ cells, 41% vs. 93% (P = 0.008), EMA+ cells, 27% vs. 60% (P = 0.113), EBV+ cells, 24% vs. 0% (P = 0.117), high nuclear grade, 70% vs. 0% (P = 0.001), total score 2-7 (mean 4.68) vs. 0-2 (mean 0.72) (P = 0.001), high stage, 86% vs. 7% (P = 0.0001).
  • [MeSH-major] Biomarkers, Tumor / analysis. Hodgkin Disease / metabolism. Hodgkin Disease / pathology. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD / biosynthesis. Antigens, Neoplasm / biosynthesis. Child. Child, Preschool. Diagnosis, Differential. Humans. Immunohistochemistry. Immunophenotyping. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063524.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


99. Larson ML, Enschede SH, Gregory SA: HIV-related lymphoma treated with maintenance thalidomide. Clin Adv Hematol Oncol; 2005 Mar;3(3):231-4; discussion 234-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-related lymphoma treated with maintenance thalidomide.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Axilla. Carboplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Immunotherapy. Lymphatic Irradiation. Male. Prednisone / administration & dosage. Randomized Controlled Trials as Topic. Remission Induction. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166993.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 4Z8R6ORS6L / Thalidomide; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; CHOP protocol; ICE protocol 3
  • [Number-of-references] 22
  •  go-up   go-down


100. Li X, Lin Q, Dong M, Wen JY, Wei L, Ma XK, Chen ZH, Wu XY: Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leuk Lymphoma; 2010 Sep;51(9):1678-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma.
  • The prognosis and management of acute exacerbations of hepatitis-B in patients with lymphoma after chemotherapy in combination with rituximab remain unclear.
  • Here, we describe 19 Chinese patients with lymphoma who suffered this complication, in order to analyze their clinical characteristics.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hepatitis B / etiology. Hepatitis B virus / physiology. Lymphoma, B-Cell, Marginal Zone / virology. Lymphoma, Follicular / virology. Lymphoma, Large B-Cell, Diffuse / virology. Virus Activation / drug effects
  • [MeSH-minor] Acute Disease. Adult. Aged. Antibodies, Monoclonal, Murine-Derived / administration & dosage. Antibodies, Monoclonal, Murine-Derived / adverse effects. Antiviral Agents / therapeutic use. Bilirubin / metabolism. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. DNA, Viral / genetics. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Follow-Up Studies. Humans. Liver Function Tests. Male. Middle Aged. Polymerase Chain Reaction. Prednisone / administration & dosage. Prednisone / adverse effects. Prognosis. Prothrombin Time. Rituximab. Survival Rate. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 Sep;51(9):1592-5 [20807092.001]
  • (PMID = 20807095.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antiviral Agents; 0 / DNA, Viral; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; RFM9X3LJ49 / Bilirubin; VB0R961HZT / Prednisone
  •  go-up   go-down






Advertisement